You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameLevetiracetam
Accession NumberDB01202  (APRD01068)
TypeSmall Molecule
GroupsApproved, Investigational
DescriptionLevetiracetam is an anticonvulsant medication used to treat epilepsy. Levetiracetam may selectively prevent hypersynchronization of epileptiform burst firing and propagation of seizure activity. Levetiracetam binds to the synaptic vesicle protein SV2A, which is thought to be involved in the regulation of vesicle exocytosis. Although the molecular significance of levetiracetam binding to synaptic vesicle protein SV2A is not understood, levetiracetam and related analogs showed a rank order of affinity for SV2A which correlated with the potency of their antiseizure activity in audiogenic seizure-prone mice.
Structure
Thumb
Synonyms
Levetiracetam
Levetiracetame
Levetiracetamum
Levitiracetam
External Identifiers
  • UCB 22059
  • UCB L059
  • UCB-22059
  • UCB-L059
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Abbott-levetiracetamTablet250 mgOralAbbott Laboratories, Limited2014-05-302015-12-31Canada
Abbott-levetiracetamTablet500 mgOralAbbott Laboratories, Limited2014-05-302015-12-31Canada
Abbott-levetiracetamTablet750 mgOralAbbott Laboratories, Limited2014-05-302015-12-31Canada
Act LevetiracetamTablet250 mgOralActavis Pharma Company2005-12-07Not applicableCanada
Act LevetiracetamTablet500 mgOralActavis Pharma Company2005-12-07Not applicableCanada
Act LevetiracetamTablet750 mgOralActavis Pharma Company2005-12-07Not applicableCanada
Auro-levetiracetamTablet500 mgOralAuro Pharma Inc2012-03-15Not applicableCanada
Auro-levetiracetamTablet750 mgOralAuro Pharma Inc2012-02-14Not applicableCanada
Auro-levetiracetamTablet250 mgOralAuro Pharma Inc2012-02-14Not applicableCanada
Ava-levetiracetamTablet250 mgOralAvanstra Inc2011-10-112014-08-21Canada
Ava-levetiracetamTablet500 mgOralAvanstra Inc2011-10-112014-08-21Canada
Ava-levetiracetamTablet750 mgOralAvanstra Inc2011-10-112014-08-21Canada
Bio-levetiracetamTablet250 mgOralBiomed PharmaNot applicableNot applicableCanada
Bio-levetiracetamTablet500 mgOralBiomed PharmaNot applicableNot applicableCanada
Bio-levetiracetamTablet750 mgOralBiomed PharmaNot applicableNot applicableCanada
Dom-levetiracetamTablet250 mgOralDominion Pharmacal2008-04-16Not applicableCanada
Dom-levetiracetamTablet500 mgOralDominion Pharmacal2008-04-16Not applicableCanada
Dom-levetiracetamTablet750 mgOralDominion Pharmacal2008-04-16Not applicableCanada
Elepsia XRTablet, extended release1000 mg/1OralSun Pharma Advanced Research Company Limited2015-03-13Not applicableUs
Elepsia XRTablet, extended release1500 mg/1OralSun Pharma Advanced Research Company Limited2015-03-13Not applicableUs
Jamp-levetiracetamTablet250 mgOralJamp Pharma Corporation2013-04-29Not applicableCanada
Jamp-levetiracetamTablet500 mgOralJamp Pharma Corporation2013-04-29Not applicableCanada
Jamp-levetiracetamTablet750 mgOralJamp Pharma Corporation2013-04-29Not applicableCanada
KeppraTablet, film coated500 mg/1OralSTAT Rx USA LLC2000-04-24Not applicableUs
KeppraTablet, film coated500 mg/1OralRx Pak Division Of Mc Kesson Corporation2014-05-16Not applicableUs
KeppraTablet, film coated750 mg/1OralUCB, Inc.2000-04-24Not applicableUs
KeppraTablet, film coated750 mg/1OralPhysicians Total Care, Inc.2005-04-15Not applicableUs
KeppraTablet1000 mg/1OralUCB Farchim S.A.2000-04-242016-04-05Us
KeppraTablet250 mgOralUcb Canada Inc2003-07-23Not applicableCanada
KeppraTablet, film coated750 mg/1OralSTAT Rx USA LLC2000-04-24Not applicableUs
KeppraTablet, film coated1000 mg/1OralRx Pak Division Of Mc Kesson Corporation2014-05-16Not applicableUs
KeppraTablet, film coated1000 mg/1OralUCB, Inc.2000-04-24Not applicableUs
KeppraSolution100 mg/mLOralUCB, Inc.2003-10-20Not applicableUs
KeppraInjection, solution, concentrate100 mg/mLIntravenousCardinal Health2006-07-31Not applicableUs
KeppraTablet500 mgOralUcb Canada Inc2003-07-23Not applicableCanada
KeppraTablet, film coated750 mg/1OralREMEDYREPACK INC.2013-02-282016-04-05Us
KeppraTablet500 mg/1OralRebel Distributors Corp2000-04-24Not applicableUs
KeppraTablet, film coated250 mg/1OralUCB, Inc.2000-04-24Not applicableUs
KeppraTablet, film coated500 mg/1OralPd Rx Pharmaceuticals, Inc.2000-04-24Not applicableUs
KeppraTablet750 mgOralUcb Canada Inc2003-07-23Not applicableCanada
KeppraInjection, solution, concentrate100 mg/mLIntravenousUCB, Inc.2006-08-23Not applicableUs
KeppraTablet, film coated500 mg/1OralPhysicians Total Care, Inc.2003-10-30Not applicableUs
KeppraTablet750 mg/1OralUCB Farchim S.A.2000-04-242016-04-05Us
KeppraTablet, film coated750 mg/1OralRx Pak Division Of Mc Kesson Corporation2014-05-16Not applicableUs
KeppraTablet, film coated500 mg/1OralUCB, Inc.2000-04-24Not applicableUs
Keppra XRTablet, film coated, extended release500 mg/1OralUCB, Inc.2008-09-24Not applicableUs
Keppra XRTablet, film coated, extended release750 mg/1OralUCB, Inc.2009-04-01Not applicableUs
Keppra XRTablet, film coated, extended release500 mg/1OralRx Pak Division Of Mc Kesson Corporation2014-05-16Not applicableUs
Keppra XRTablet, film coated, extended release750 mg/1OralRx Pak Division Of Mc Kesson Corporation2014-05-16Not applicableUs
LevetiracetamTablet250 mgOralSanis Health Inc2010-07-26Not applicableCanada
LevetiracetamTablet500 mgOralSivem Pharmaceuticals Ulc2015-07-22Not applicableCanada
LevetiracetamTablet750 mgOralPharmascience Inc2016-11-01Not applicableCanada
LevetiracetamTablet750 mgOralCobalt Pharmaceuticals CompanyNot applicableNot applicableCanada
LevetiracetamInjection15 mg/mLIntravenousMylan Institutional LLC2011-11-10Not applicableUs
LevetiracetamTablet500 mgOralSanis Health Inc2010-07-26Not applicableCanada
LevetiracetamTablet250 mgOralJubilant Generics LimitedNot applicableNot applicableCanada
LevetiracetamTablet750 mgOralSivem Pharmaceuticals Ulc2015-07-22Not applicableCanada
LevetiracetamTablet750 mgOralSanis Health Inc2010-07-26Not applicableCanada
LevetiracetamTablet500 mgOralJubilant Generics LimitedNot applicableNot applicableCanada
LevetiracetamTablet250 mgOralPharmascience Inc2016-11-01Not applicableCanada
LevetiracetamTablet250 mgOralCobalt Pharmaceuticals CompanyNot applicableNot applicableCanada
LevetiracetamInjection5 mg/mLIntravenousMylan Institutional LLC2011-11-10Not applicableUs
LevetiracetamTablet250 mgOralSivem Pharmaceuticals Ulc2015-07-22Not applicableCanada
LevetiracetamTablet750 mgOralJubilant Generics LimitedNot applicableNot applicableCanada
LevetiracetamTablet500 mgOralPharmascience Inc2016-11-01Not applicableCanada
LevetiracetamInjection10 mg/mLIntravenousMylan Institutional LLC2011-11-10Not applicableUs
LevetiracetamTablet500 mgOralCobalt Pharmaceuticals CompanyNot applicableNot applicableCanada
Levetiracetam TabletsTablet250 mgOralAccord Healthcare Inc2013-03-20Not applicableCanada
Levetiracetam TabletsTablet500 mgOralAccord Healthcare Inc2013-03-20Not applicableCanada
Levetiracetam TabletsTablet750 mgOralAccord Healthcare Inc2013-03-20Not applicableCanada
Mint-levetiracetamTablet250 mgOralMint Pharmaceuticals IncNot applicableNot applicableCanada
Mint-levetiracetamTablet500 mgOralMint Pharmaceuticals IncNot applicableNot applicableCanada
Mint-levetiracetamTablet750 mgOralMint Pharmaceuticals IncNot applicableNot applicableCanada
Nat-levetiracetamTablet250 mgOralNatco Pharma (Canada) Inc2015-07-22Not applicableCanada
Nat-levetiracetamTablet500 mgOralNatco Pharma (Canada) Inc2015-07-22Not applicableCanada
Nat-levetiracetamTablet750 mgOralNatco Pharma (Canada) Inc2015-07-22Not applicableCanada
Novo-levetiracetamTablet750 mgOralNovopharm LimitedNot applicableNot applicableCanada
Nu-levetiracetamTablet500 mgOralNu Pharm IncNot applicableNot applicableCanada
Nu-levetiracetamTablet750 mgOralNu Pharm IncNot applicableNot applicableCanada
Nu-levetiracetamTablet250 mgOralNu Pharm IncNot applicableNot applicableCanada
PHL-levetiracetamTablet750 mgOralPharmel Inc2008-04-16Not applicableCanada
PHL-levetiracetamTablet250 mgOralPharmel Inc2008-04-16Not applicableCanada
PHL-levetiracetamTablet500 mgOralPharmel Inc2008-04-16Not applicableCanada
PMS-levetiracetamTablet500 mgOralPharmascience Inc2007-06-07Not applicableCanada
PMS-levetiracetamTablet750 mgOralPharmascience Inc2007-06-07Not applicableCanada
PMS-levetiracetamTablet250 mgOralPharmascience Inc2007-06-07Not applicableCanada
Priva-levetiracetamTablet500 mgOralPharmapar IncNot applicableNot applicableCanada
Priva-levetiracetamTablet750 mgOralPharmapar IncNot applicableNot applicableCanada
Priva-levetiracetamTablet250 mgOralPharmapar IncNot applicableNot applicableCanada
Pro-levetiracetam - 250Tablet250 mgOralPro Doc Limitee2013-06-06Not applicableCanada
Pro-levetiracetam - 500Tablet500 mgOralPro Doc Limitee2009-06-16Not applicableCanada
Pro-levetiracetam - 750Tablet750 mgOralPro Doc Limitee2009-10-08Not applicableCanada
Ran-levetiracetamTablet750 mgOralRanbaxy Pharmaceuticals Canada Inc.2013-03-22Not applicableCanada
Ran-levetiracetamTablet250 mgOralRanbaxy Pharmaceuticals Canada Inc.2013-03-22Not applicableCanada
Ran-levetiracetamTablet500 mgOralRanbaxy Pharmaceuticals Canada Inc.2013-03-22Not applicableCanada
SpritamTablet, for suspension750 mg/1OralAprecia Pharmaceuticals Company2016-02-05Not applicableUs
SpritamTablet, for suspension1000 mg/1OralAprecia Pharmaceuticals Company2016-02-05Not applicableUs
SpritamTablet, for suspension250 mg/1OralAprecia Pharmaceuticals Company2016-02-05Not applicableUs
SpritamTablet, for suspension500 mg/1OralAprecia Pharmaceuticals Company2016-02-05Not applicableUs
Torrent-levetiracetamTablet750 mgOralTorrent Pharmaceuticals LimitedNot applicableNot applicableCanada
Torrent-levetiracetamTablet250 mgOralTorrent Pharmaceuticals LimitedNot applicableNot applicableCanada
Torrent-levetiracetamTablet500 mgOralTorrent Pharmaceuticals LimitedNot applicableNot applicableCanada
Van-levetiracetamTablet750 mgOralVanc Pharmaceuticals Inc2016-04-04Not applicableCanada
Van-levetiracetamTablet250 mgOralVanc Pharmaceuticals Inc2016-04-04Not applicableCanada
Van-levetiracetamTablet500 mgOralVanc Pharmaceuticals Inc2016-04-04Not applicableCanada
Approved Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Apo-levetiracetamTablet250 mgOralApotex Inc2006-10-20Not applicableCanada
Apo-levetiracetamTablet500 mgOralApotex Inc2006-10-20Not applicableCanada
Apo-levetiracetamTablet750 mgOralApotex Inc2006-10-20Not applicableCanada
LevetiracetamTablet, film coated250 mg/1OralMylan Pharmaceuticals Inc.2008-11-04Not applicableUs
LevetiracetamTablet500 mg/1OralREMEDYREPACK INC.2011-09-21Not applicableUs
LevetiracetamTablet, film coated1000 mg/1OralBlue Point Laboratories2014-02-24Not applicableUs
LevetiracetamTablet, film coated250 mg/1OralNcs Health Care Of Ky, Inc Dba Vangard Labs2012-01-09Not applicableUs
LevetiracetamSolution100 mg/mLOralPharmaceutical Associates, Inc.2009-02-11Not applicableUs
LevetiracetamTablet, film coated750 mg/1OralREMEDYREPACK INC.2016-06-28Not applicableUs
LevetiracetamTablet750 mg/1OralMajor Pharmaceuticals2013-08-02Not applicableUs
LevetiracetamSolution100 mg/mLOralActavis Pharma, Inc.2009-01-15Not applicableUs
LevetiracetamTablet, film coated250 mg/1OralAccord Healthcare Inc.2011-03-14Not applicableUs
LevetiracetamTablet, film coated500 mg/1OralAmneal Pharmaceuticals of New York, LLC2013-02-28Not applicableUs
LevetiracetamTablet, film coated500 mg/1OralCamber Pharmaceuticals2012-01-09Not applicableUs
LevetiracetamTablet, film coated750 mg/1OralAmerican Health Packaging2012-04-022016-09-30Us
LevetiracetamTablet, film coated500 mg/1OralRebel Distributors Corp2011-09-01Not applicableUs
LevetiracetamTablet, film coated1000 mg/1OralTeva Pharmaceuticals USA Inc2009-01-152015-11-30Us
LevetiracetamTablet, film coated250 mg/1OralAv Pak2009-03-20Not applicableUs
LevetiracetamTablet, film coated500 mg/1OralSolco Healthcare US, LLC2012-09-11Not applicableUs
LevetiracetamTablet, film coated750 mg/1OralTaro Pharmaceuticals U.S.A., Inc.2010-02-01Not applicableUs
LevetiracetamTablet500 mg/1OralPhysicians Total Care, Inc.2009-10-15Not applicableUs
LevetiracetamTablet, film coated250 mg/1OralREMEDYREPACK INC.2015-07-03Not applicableUs
LevetiracetamTablet, film coated500 mg/1OralNorth Star Rx Llc2009-01-15Not applicableUs
LevetiracetamTablet, film coated, extended release1000 mg/1OralApotex Corp.2015-02-25Not applicableUs
LevetiracetamTablet, film coated250 mg/1OralLUPIN LIMITED2009-01-01Not applicableUs
LevetiracetamSolution100 mg/mLOralRoxane Laboratories, Inc2009-01-15Not applicableUs
LevetiracetamTablet, film coated500 mg/1OralA S Medication Solutions2012-01-09Not applicableUs
LevetiracetamTablet, film coated250 mg/1OralNcs Health Care Of Ky, Inc Dba Vangard Labs2008-11-04Not applicableUs
LevetiracetamTablet, extended release750 mg/1OralTorrent Pharmaceuticals Limited2012-05-29Not applicableUs
LevetiracetamTablet, film coated750 mg/1OralAurobindo Pharma Limited2009-01-15Not applicableUs
LevetiracetamTablet, film coated750 mg/1Oralbryant ranch prepack2009-01-01Not applicableUs
LevetiracetamTablet250 mg/1OralRebel Distributors Corp2009-10-15Not applicableUs
LevetiracetamSolution100 mg/mLOralVista Pharm, Inc2010-01-25Not applicableUs
LevetiracetamTablet, film coated500 mg/1OralLake Erie Medical & Surgical Supply DBA Quality Care Products LLC2012-01-23Not applicableUs
LevetiracetamTablet500 mg/1OralExelan Pharmaceuticals, Inc.2009-01-15Not applicableUs
LevetiracetamTablet, film coated, extended release750 mg/1OralSolco Healthcare US, LLC2014-05-01Not applicableUs
LevetiracetamTablet, extended release500 mg/1OralLUPIN LIMITED2011-09-12Not applicableUs
LevetiracetamTablet, film coated500 mg/1OralMylan Institutional Inc.2008-11-04Not applicableUs
LevetiracetamTablet, film coated1000 mg/1OralLupin Pharmaceuticals, Inc.2009-01-15Not applicableUs
LevetiracetamTablet, film coated1000 mg/1OralLucid Pharma Llc2014-11-06Not applicableUs
LevetiracetamTablet, film coated500 mg/1OralCardinal Health2011-09-26Not applicableUs
LevetiracetamTablet, film coated1000 mg/1OralREMEDYREPACK INC.2016-01-12Not applicableUs
LevetiracetamTablet, film coated250 mg/1OralUnit Dose Services2009-01-01Not applicableUs
LevetiracetamTablet, film coated500 mg/1OralCardinal Health2012-08-29Not applicableUs
LevetiracetamTablet1000 mg/1OralBreckenridge Pharmaceutical, Inc.2011-11-01Not applicableUs
LevetiracetamTablet250 mg/1OralDr. Reddy's Laboratories Limited2009-01-15Not applicableUs
LevetiracetamInjection100 mg/mLIntravenousSun Pharmaceutical Industries Limited2010-06-17Not applicableUs
LevetiracetamInjection100 mg/mLIntravenousHospira, Inc.2012-04-06Not applicableUs
LevetiracetamTablet, film coated750 mg/1OralClinical Solutions Wholesale2009-01-01Not applicableUs
LevetiracetamTablet, extended release500 mg/1OralLupin Pharmaceuticals, Inc.2011-09-12Not applicableUs
LevetiracetamInjection, solution, concentrate100 mg/mLIntravenousAmerican Regent, Inc.2012-02-21Not applicableUs
LevetiracetamTablet, film coated, extended release750 mg/1OralQuinn Pharmaceuticals, Llc2016-06-01Not applicableUs
LevetiracetamTablet500 mg/1OralTorrent Pharmaceuticals Limited2009-01-15Not applicableUs
LevetiracetamTablet, film coated500 mg/1OralSecan Pharmaceuticals, Inc.2016-08-15Not applicableUs
LevetiracetamSolution100 mg/mLOralAtlantic Biologicals Corps2009-10-27Not applicableUs
LevetiracetamTablet, film coated250 mg/1OralHetero Drugs Ltd.,2010-10-08Not applicableUs
LevetiracetamTablet, film coated250 mg/1OralAidarex Pharmaceuticals LLC2009-01-01Not applicableUs
LevetiracetamTablet, film coated250 mg/1OralDispensing Solutions, Inc.2009-01-15Not applicableUs
LevetiracetamTablet, film coated500 mg/1OralPd Rx Pharmaceuticals, Inc.2009-01-01Not applicableUs
LevetiracetamTablet, film coated1000 mg/1OralMethapharm, Inc.2010-10-18Not applicableUs
LevetiracetamTablet, film coated500 mg/1OralKaralex Pharma LLC2011-09-01Not applicableUs
LevetiracetamTablet, film coated750 mg/1OralPrinston Pharmaceutical Inc.2012-09-11Not applicableUs
LevetiracetamTablet250 mg/1OralREMEDYREPACK INC.2011-12-07Not applicableUs
LevetiracetamSolution100 mg/mLOralSilarx Pharmaceuticals, Inc.2009-04-03Not applicableUs
LevetiracetamTablet, film coated1000 mg/1OralTaro Pharmaceuticals U.S.A., Inc.2010-02-01Not applicableUs
LevetiracetamTablet, film coated1000 mg/1OralAjanta Pharma Limited2015-08-10Not applicableUs
LevetiracetamTablet, film coated500 mg/1OralState of Florida DOH Central Pharmacy2013-09-01Not applicableUs
LevetiracetamInjection, solution, concentrate500 mg/5mLIntravenousX Gen Pharmaceuticals, Inc.2011-08-05Not applicableUs
LevetiracetamTablet, film coated500 mg/1OralDIRECT RX2014-01-01Not applicableUs
LevetiracetamTablet, film coated750 mg/1OralREMEDYREPACK INC.2016-02-12Not applicableUs
LevetiracetamTablet, film coated, extended release750 mg/1OralTeva Pharmaceuticals USA Inc2011-09-142016-09-30Us
LevetiracetamTablet, film coated750 mg/1OralCitron Pharma LLC2009-01-15Not applicableUs
LevetiracetamTablet1000 mg/1OralNcs Health Care Of Ky, Inc Dba Vangard Labs2009-01-15Not applicableUs
LevetiracetamTablet, film coated750 mg/1OralAmerican Health Packaging2014-12-15Not applicableUs
LevetiracetamTablet250 mg/1OralSTAT Rx USA LLC2009-01-15Not applicableUs
LevetiracetamTablet, film coated750 mg/1OralBoca Pharmacal, LLC2014-09-12Not applicableUs
LevetiracetamSolution100 mg/mLOralLLC Federal Solutions2013-09-24Not applicableUs
LevetiracetamTablet, film coated500 mg/1OralMylan Pharmaceuticals Inc.2008-11-04Not applicableUs
LevetiracetamSolution100 mg/mLOralBreckenridge Pharmaceutical, Inc.2013-11-19Not applicableUs
LevetiracetamTablet, film coated250 mg/1OralBlue Point Laboratories2014-02-24Not applicableUs
LevetiracetamTablet, film coated500 mg/1OralNcs Health Care Of Ky, Inc Dba Vangard Labs2012-01-09Not applicableUs
LevetiracetamTablet, film coated1000 mg/1OralActavis Elizabeth LLC2011-04-04Not applicableUs
LevetiracetamTablet, film coated500 mg/1OralREMEDYREPACK INC.2016-07-26Not applicableUs
LevetiracetamTablet250 mg/1OralREMEDYREPACK INC.2011-10-17Not applicableUs
LevetiracetamTablet, film coated500 mg/1OralAccord Healthcare Inc.2011-03-14Not applicableUs
LevetiracetamTablet, film coated750 mg/1OralAmneal Pharmaceuticals of New York, LLC2013-02-28Not applicableUs
LevetiracetamTablet, film coated750 mg/1OralCamber Pharmaceuticals2012-01-09Not applicableUs
LevetiracetamTablet, film coated1000 mg/1OralAmerican Health Packaging2010-12-292016-10-31Us
LevetiracetamTablet, film coated1000 mg/1OralRebel Distributors Corp2011-09-01Not applicableUs
LevetiracetamTablet, film coated500 mg/1OralCardinal Health2009-11-192015-12-29Us
LevetiracetamTablet, film coated500 mg/1OralAv Pak2009-03-20Not applicableUs
LevetiracetamTablet, film coated750 mg/1OralSolco Healthcare US, LLC2012-09-11Not applicableUs
LevetiracetamTablet250 mg/1OralBreckenridge Pharmaceutical, Inc.2011-11-01Not applicableUs
LevetiracetamTablet1000 mg/1OralPhysicians Total Care, Inc.2009-10-15Not applicableUs
LevetiracetamTablet, film coated500 mg/1OralREMEDYREPACK INC.2015-10-09Not applicableUs
LevetiracetamTablet, film coated750 mg/1OralNorth Star Rx Llc2009-01-15Not applicableUs
LevetiracetamTablet, film coated250 mg/1OralREMEDYREPACK INC.2015-02-13Not applicableUs
LevetiracetamTablet, film coated500 mg/1OralLUPIN LIMITED2009-01-01Not applicableUs
LevetiracetamTablet, film coated500 mg/1OralTeva Pharmaceuticals USA Inc2009-01-152016-04-30Us
LevetiracetamTablet, film coated250 mg/1OralREMEDYREPACK INC.2012-10-22Not applicableUs
LevetiracetamTablet, film coated500 mg/1OralNcs Health Care Of Ky, Inc Dba Vangard Labs2013-02-06Not applicableUs
LevetiracetamTablet, film coated500 mg/1OralTrigen Laboratories, Inc.2012-03-31Not applicableUs
LevetiracetamTablet, film coated1000 mg/1OralAurobindo Pharma Limited2009-01-15Not applicableUs
LevetiracetamSolution100 mg/mLOralMc Kesson Packaging Services A Business Unit Of Mc Kesson Corporation2011-11-01Not applicableUs
LevetiracetamTablet750 mg/1OralRebel Distributors Corp2009-10-15Not applicableUs
LevetiracetamTablet, film coated250 mg/1OralMethapharm, Inc.2010-10-18Not applicableUs
LevetiracetamTablet, film coated750 mg/1OralLake Eire Medical & Surgical Supply DBA Quality Care Products LLC2011-11-14Not applicableUs
LevetiracetamTablet750 mg/1OralExelan Pharmaceuticals, Inc.2009-01-15Not applicableUs
LevetiracetamTablet750 mg/1OralREMEDYREPACK INC.2010-11-082016-10-26Us
LevetiracetamTablet, extended release750 mg/1OralLUPIN LIMITED2011-09-12Not applicableUs
LevetiracetamTablet, film coated750 mg/1OralMylan Institutional Inc.2008-11-04Not applicableUs
LevetiracetamTablet, film coated250 mg/1OralAjanta Pharma Limited2015-08-10Not applicableUs
LevetiracetamTablet, film coated500 mg/1OralState of Florida DOH Central Pharmacy2009-07-01Not applicableUs
LevetiracetamSolution100 mg/mLOralCardinal Health2009-09-20Not applicableUs
LevetiracetamTablet, film coated500 mg/1OralHetero Drugs Ltd.,2010-10-08Not applicableUs
LevetiracetamTablet, film coated500 mg/1OralAidarex Pharmaceuticals LLC2009-01-01Not applicableUs
LevetiracetamTablet, film coated500 mg/1OralMc Kesson Contract Packaging2011-10-12Not applicableUs
LevetiracetamTablet, film coated250 mg/1OralSecan Pharmaceuticals, Inc.2015-12-182016-11-09Us
LevetiracetamTablet, film coated750 mg/1OralUnit Dose Services2009-01-01Not applicableUs
LevetiracetamTablet, film coated250 mg/1OralLupin Pharmaceuticals, Inc.2009-01-01Not applicableUs
LevetiracetamTablet, film coated250 mg/1OralLucid Pharma Llc2014-11-06Not applicableUs
LevetiracetamTablet500 mg/1OralDr. Reddy's Laboratories Limited2009-01-15Not applicableUs
LevetiracetamInjection, solution100 mg/mLIntravenousFresenius Kabi USA, LLC2010-06-03Not applicableUs
LevetiracetamTablet, film coated, extended release500 mg/1OralQualitest Pharmaceuticals2012-07-202016-10-26Us
LevetiracetamTablet, film coated1000 mg/1OralClinical Solutions Wholesale2009-01-15Not applicableUs
LevetiracetamTablet, extended release750 mg/1OralLupin Pharmaceuticals, Inc.2011-09-12Not applicableUs
LevetiracetamTablet, film coated, extended release500 mg/1OralActavis Pharma, Inc.2011-09-12Not applicableUs
LevetiracetamTablet, film coated500 mg/1OralA S Medication Solutions2012-09-11Not applicableUs
LevetiracetamTablet750 mg/1OralTorrent Pharmaceuticals Limited2009-01-15Not applicableUs
LevetiracetamTablet, film coated250 mg/1OralREMEDYREPACK INC.2016-11-17Not applicableUs
LevetiracetamSolution100 mg/mLOralAtlantic Biologicals Corps2009-01-16Not applicableUs
LevetiracetamTablet, film coated1000 mg/1OralAmerican Health Packaging2014-12-15Not applicableUs
LevetiracetamTablet500 mg/1OralSTAT Rx USA LLC2009-01-15Not applicableUs
LevetiracetamTablet, film coated500 mg/1OralTYA Pharmaceuticals2009-01-01Not applicableUs
LevetiracetamInjection, solution, concentrate500 mg/5mLIntravenousSagent Pharmaceuticals2013-11-01Not applicableUs
LevetiracetamTablet, film coated250 mg/1OralAmerican Health Packaging2010-01-282016-09-30Us
LevetiracetamTablet, film coated750 mg/1OralKaralex Pharma LLC2011-09-01Not applicableUs
LevetiracetamTablet, film coated1000 mg/1OralPrinston Pharmaceutical Inc.2012-09-11Not applicableUs
LevetiracetamTablet, extended release500 mg/1OralPar Pharmaceutical Inc.2011-09-13Not applicableUs
LevetiracetamSolution100 mg/mLOralSandoz Inc.2009-01-15Not applicableUs
LevetiracetamTablet, film coated250 mg/1OralTaro Pharmaceuticals U.S.A., Inc.2010-02-01Not applicableUs
LevetiracetamTablet, film coated500 mg/1OralState of Florida DOH Central Pharmacy2014-01-01Not applicableUs
LevetiracetamSolution100 mg/mLOralMorton Grove Pharmaceuticals, Inc.2010-03-18Not applicableUs
LevetiracetamInjection100 mg/mLIntravenousWest Ward Pharmaceuticals Corp2015-06-01Not applicableUs
LevetiracetamTablet, film coated, extended release500 mg/1OralSun Pharma Global FZE2013-09-09Not applicableUs
LevetiracetamTablet, extended release500 mg/1OralBlue Point Laboratories2014-02-13Not applicableUs
LevetiracetamTablet, film coated1000 mg/1OralREMEDYREPACK INC.2016-03-01Not applicableUs
LevetiracetamSolution100 mg/mLOralPharmaceutical Associates, Inc.2015-06-04Not applicableUs
LevetiracetamTablet, film coated1000 mg/1OralCitron Pharma LLC2009-01-15Not applicableUs
LevetiracetamTablet250 mg/1OralMajor Pharmaceuticals2013-08-02Not applicableUs
LevetiracetamTablet, film coated750 mg/1OralMylan Pharmaceuticals Inc.2008-11-04Not applicableUs
LevetiracetamSolution100 mg/mLOralCardinal Health2011-11-01Not applicableUs
LevetiracetamTablet, film coated500 mg/1OralBlue Point Laboratories2014-02-24Not applicableUs
LevetiracetamTablet, film coated750 mg/1OralNcs Health Care Of Ky, Inc Dba Vangard Labs2012-01-09Not applicableUs
LevetiracetamTablet, film coated, extended release750 mg/1OralActavis Elizabeth LLC2011-09-12Not applicableUs
LevetiracetamTablet, film coated500 mg/1OralProficient Rx LP2009-01-01Not applicableUs
LevetiracetamTablet, film coated250 mg/1OralPreferred Pharmaceuticals, Inc.2016-11-03Not applicableUs
LevetiracetamTablet, film coated750 mg/1OralAccord Healthcare Inc.2011-03-14Not applicableUs
LevetiracetamTablet, film coated1000 mg/1OralAmneal Pharmaceuticals of New York, LLC2013-02-28Not applicableUs
LevetiracetamTablet, film coated1000 mg/1OralCamber Pharmaceuticals2012-01-09Not applicableUs
LevetiracetamSolution100 mg/mLOralLupin Pharmaceuticals, Inc.2014-11-01Not applicableUs
LevetiracetamTablet, film coated250 mg/1OralRebel Distributors Corp2009-01-01Not applicableUs
LevetiracetamTablet, film coated750 mg/1OralCardinal Health2009-11-192015-12-29Us
LevetiracetamTablet, film coated750 mg/1OralAv Pak2009-03-20Not applicableUs
LevetiracetamTablet, film coated1000 mg/1OralSolco Healthcare US, LLC2012-09-11Not applicableUs
LevetiracetamTablet500 mg/1OralBreckenridge Pharmaceutical, Inc.2011-11-01Not applicableUs
LevetiracetamTablet750 mg/1OralPhysicians Total Care, Inc.2011-06-07Not applicableUs
LevetiracetamTablet, film coated500 mg/1OralREMEDYREPACK INC.2015-11-12Not applicableUs
LevetiracetamSolution100 mg/5mLOralGolden State Medical Supply, Inc.2009-02-10Not applicableUs
LevetiracetamTablet, film coated1000 mg/1OralNorth Star Rx Llc2009-01-15Not applicableUs
LevetiracetamTablet, film coated500 mg/1OralREMEDYREPACK INC.2015-02-26Not applicableUs
LevetiracetamTablet, film coated750 mg/1OralLUPIN LIMITED2009-01-01Not applicableUs
LevetiracetamTablet, film coated750 mg/1OralTeva Pharmaceuticals USA Inc2009-01-152016-02-29Us
LevetiracetamTablet, film coated250 mg/1OralCitron Pharma LLC2009-01-15Not applicableUs
LevetiracetamTablet, film coated750 mg/1OralNcs Health Care Of Ky, Inc Dba Vangard Labs2013-02-06Not applicableUs
LevetiracetamTablet, film coated250 mg/1OralAmerican Health Packaging2014-12-15Not applicableUs
LevetiracetamInjection, solution100 mg/mLIntravenousNexus Pharmaceuticals Inc2010-06-03Not applicableUs
LevetiracetamTablet, film coated500 mg/1OralPreferred Pharmaceuticals, Inc.2016-12-05Not applicableUs
LevetiracetamTablet, film coated250 mg/1OralBoca Pharmacal, LLC2014-09-12Not applicableUs
LevetiracetamTablet, film coated250 mg/1OralREMEDYREPACK INC.2013-03-182016-11-02Us
LevetiracetamTablet, film coated500 mg/1OralMethapharm, Inc.2010-10-18Not applicableUs
LevetiracetamTablet, film coated500 mg/1OralLotus Pharmaceutical Co., Ltd. Nantou Plant2015-03-062016-01-09Us
LevetiracetamTablet, film coated250 mg/1OralPrinston Pharmaceutical Inc.2012-09-11Not applicableUs
LevetiracetamTablet500 mg/1OralREMEDYREPACK INC.2011-10-122016-11-30Us
LevetiracetamTablet, film coated500 mg/1OralREMEDYREPACK INC.2016-02-25Not applicableUs
LevetiracetamTablet, film coated1000 mg/1OralMylan Institutional Inc.2010-03-24Not applicableUs
LevetiracetamTablet, film coated500 mg/1OralAjanta Pharma Limited2015-08-10Not applicableUs
LevetiracetamTablet, film coated500 mg/1OralState of Florida DOH Central Pharmacy2009-07-01Not applicableUs
LevetiracetamTablet, film coated500 mg/1OralREMEDYREPACK INC.2016-10-24Not applicableUs
LevetiracetamTablet1000 mg/1OralTorrent Pharmaceuticals Limited2009-01-15Not applicableUs
LevetiracetamTablet, film coated250 mg/1OralAurobindo Pharma Limited2009-01-15Not applicableUs
LevetiracetamTablet500 mg/1OralRebel Distributors Corp2009-10-15Not applicableUs
LevetiracetamTablet, film coated750 mg/1OralHetero Drugs Ltd.,2010-10-08Not applicableUs
LevetiracetamTablet, film coated750 mg/1OralAidarex Pharmaceuticals LLC2009-01-01Not applicableUs
LevetiracetamTablet, film coated750 mg/1OralMc Kesson Contract Packaging2011-11-23Not applicableUs
LevetiracetamTablet, film coated750 mg/1OralSecan Pharmaceuticals, Inc.2015-12-182016-11-09Us
LevetiracetamTablet, film coated500 mg/1OralUnit Dose Services2009-01-01Not applicableUs
LevetiracetamTablet, film coated500 mg/1OralLupin Pharmaceuticals, Inc.2009-01-01Not applicableUs
LevetiracetamTablet, film coated500 mg/1OralLucid Pharma Llc2014-11-06Not applicableUs
LevetiracetamTablet750 mg/1OralDr. Reddy's Laboratories Limited2009-01-15Not applicableUs
LevetiracetamTablet, film coated500 mg/1Oralbryant ranch prepack2009-01-01Not applicableUs
LevetiracetamTablet, film coated, extended release750 mg/1OralQualitest Pharmaceuticals2012-07-20Not applicableUs
LevetiracetamTablet, film coated, extended release500 mg/1OralApotex Corp.2011-09-12Not applicableUs
LevetiracetamTablet, film coated, extended release500 mg/1OralAv Kare, Inc.2016-07-28Not applicableUs
LevetiracetamTablet, film coated, extended release750 mg/1OralActavis Pharma, Inc.2011-09-12Not applicableUs
LevetiracetamTablet, film coated250 mg/1OralREMEDYREPACK INC.2016-03-14Not applicableUs
LevetiracetamSolution100 mg/mLOralPharmaceutical Associates, Inc.2015-06-04Not applicableUs
LevetiracetamInjection, solution, concentrate100 mg/mLIntravenousJubilant Cadista Pharmaceuticals Inc.2016-06-02Not applicableUs
LevetiracetamTablet500 mg/1OralMajor Pharmaceuticals2009-07-31Not applicableUs
LevetiracetamSolution100 mg/mLOralAtlantic Biologicals Corps.2012-02-28Not applicableUs
LevetiracetamTablet750 mg/1OralSTAT Rx USA LLC2009-01-15Not applicableUs
LevetiracetamTablet, film coated250 mg/1OralAmneal Pharmaceuticals of New York, LLC2013-02-28Not applicableUs
LevetiracetamTablet, film coated250 mg/1OralCamber Pharmaceuticals2012-01-09Not applicableUs
LevetiracetamTablet, film coated500 mg/1OralAmerican Health Packaging2010-01-282016-10-31Us
LevetiracetamTablet, film coated1000 mg/1OralKaralex Pharma LLC2011-09-01Not applicableUs
LevetiracetamTablet, film coated250 mg/1OralTeva Pharmaceuticals USA Inc2009-01-152015-11-30Us
LevetiracetamTablet, extended release750 mg/1OralPar Pharmaceutical Inc.2011-09-13Not applicableUs
LevetiracetamTablet, film coated250 mg/1OralSolco Healthcare US, LLC2012-09-11Not applicableUs
LevetiracetamTablet, film coated500 mg/1OralTaro Pharmaceuticals U.S.A., Inc.2010-02-01Not applicableUs
LevetiracetamTablet, film coated750 mg/1OralState of Florida DOH Central Pharmacy2014-11-01Not applicableUs
LevetiracetamTablet, film coated250 mg/1OralREMEDYREPACK INC.2015-06-19Not applicableUs
LevetiracetamInjection100 mg/mLIntravenousWest Ward Pharmaceuticals Corp2011-10-13Not applicableUs
LevetiracetamTablet, film coated, extended release750 mg/1OralSun Pharma Global FZE2013-09-09Not applicableUs
LevetiracetamTablet, extended release750 mg/1OralBlue Point Laboratories2014-02-13Not applicableUs
LevetiracetamTablet, film coated, extended release500 mg/1OralPhysicians Total Care, Inc.2011-11-22Not applicableUs
LevetiracetamTablet250 mg/1OralDIRECT RX2014-01-01Not applicableUs
LevetiracetamTablet, film coated1000 mg/1OralMylan Pharmaceuticals Inc.2009-12-10Not applicableUs
LevetiracetamTablet, film coated500 mg/1OralClinical Solutions Wholesale2009-01-01Not applicableUs
LevetiracetamTablet, film coated750 mg/1OralBlue Point Laboratories2014-02-24Not applicableUs
LevetiracetamTablet, film coated1000 mg/1OralNcs Health Care Of Ky, Inc Dba Vangard Labs2009-01-15Not applicableUs
LevetiracetamTablet, film coated, extended release500 mg/1OralActavis Elizabeth LLC2011-09-12Not applicableUs
LevetiracetamTablet, film coated, extended release500 mg/1OralQuinn Pharmaceuticals, Llc2016-06-01Not applicableUs
LevetiracetamTablet250 mg/1OralTorrent Pharmaceuticals Limited2009-01-15Not applicableUs
LevetiracetamTablet, film coated1000 mg/1OralSecan Pharmaceuticals, Inc.2015-12-18Not applicableUs
LevetiracetamTablet, film coated1000 mg/1OralAccord Healthcare Inc.2011-03-14Not applicableUs
LevetiracetamSolution100 mg/mLOralAmneal Pharmaceuticals of New York, LLC2009-10-27Not applicableUs
LevetiracetamSolution100 mg/mLOralLupin Pharmaceuticals, Inc.2013-01-252016-07-31Us
LevetiracetamTablet500 mg/1OralPd Rx Pharmaceuticals, Inc.2009-01-15Not applicableUs
LevetiracetamTablet, film coated750 mg/1OralREMEDYREPACK INC.2016-01-07Not applicableUs
LevetiracetamSolution100 mg/mLOralHi Tech Pharmacal Co., Inc.2012-02-28Not applicableUs
LevetiracetamTablet, film coated250 mg/1OralCardinal Health2012-08-29Not applicableUs
LevetiracetamTablet750 mg/1OralBreckenridge Pharmaceutical, Inc.2011-11-01Not applicableUs
LevetiracetamSolution100 mg/mLOralCardinal Health2015-06-04Not applicableUs
LevetiracetamSolution100 mg/mLOralTaro Pharmaceuticals U.S.A., Inc.2009-02-10Not applicableUs
LevetiracetamTablet, film coated750 mg/1OralAjanta Pharma Limited2015-08-10Not applicableUs
LevetiracetamTablet, film coated500 mg/1OralState of Florida DOH Central Pharmacy2013-01-01Not applicableUs
LevetiracetamSolution100 mg/mLOralNorth Star Rx Llc2009-01-15Not applicableUs
LevetiracetamTablet, film coated500 mg/1OralREMEDYREPACK INC.2015-11-11Not applicableUs
LevetiracetamTablet, film coated1000 mg/1OralLUPIN LIMITED2009-01-15Not applicableUs
LevetiracetamTablet, film coated, extended release500 mg/1OralTeva Pharmaceuticals USA Inc2011-09-142016-09-30Us
LevetiracetamTablet, film coated500 mg/1OralCitron Pharma LLC2009-01-15Not applicableUs
LevetiracetamTablet1000 mg/1OralNcs Health Care Of Ky, Inc Dba Vangard Labs2009-01-15Not applicableUs
LevetiracetamTablet, film coated500 mg/1OralAmerican Health Packaging2014-12-15Not applicableUs
LevetiracetamSolution100 mg/mLOralOrit Laboratories LLC2012-04-30Not applicableUs
LevetiracetamSolution100 mg/mLOralAurobindo Pharma Limited2009-01-15Not applicableUs
LevetiracetamTablet, film coated500 mg/1OralBoca Pharmacal, LLC2014-09-12Not applicableUs
LevetiracetamTablet, film coated500 mg/1OralREMEDYREPACK INC.2013-05-062016-11-02Us
LevetiracetamTablet, film coated750 mg/1OralMethapharm, Inc.2010-10-18Not applicableUs
LevetiracetamTablet, film coated250 mg/1OralKaralex Pharma LLC2011-09-01Not applicableUs
LevetiracetamTablet, film coated500 mg/1OralPrinston Pharmaceutical Inc.2012-09-11Not applicableUs
LevetiracetamInjection, solution500 mg/5mLIntravenousAuro Medics Pharma Llc2016-02-01Not applicableUs
LevetiracetamTablet, film coated, extended release750 mg/1OralAv Kare, Inc.2016-07-28Not applicableUs
LevetiracetamSolution100 mg/mLOralQualitest Pharmaceuticals2012-04-112016-10-20Us
LevetiracetamSolution100 mg/mLOralTris Pharma Inc2012-10-192016-11-18Us
LevetiracetamTablet, extended release500 mg/1OralTorrent Pharmaceuticals Limited2012-05-29Not applicableUs
LevetiracetamTablet, film coated500 mg/1OralAurobindo Pharma Limited2009-01-15Not applicableUs
LevetiracetamTablet1000 mg/1OralRebel Distributors Corp2009-10-15Not applicableUs
LevetiracetamTablet, film coated1000 mg/1OralHetero Drugs Ltd.,2010-10-08Not applicableUs
LevetiracetamTablet, film coated250 mg/1OralLake Erie Medical & Surgical Supply DBA Quality Care Products LLC2012-01-23Not applicableUs
LevetiracetamTablet250 mg/1OralExelan Pharmaceuticals, Inc.2009-01-15Not applicableUs
LevetiracetamTablet, film coated, extended release500 mg/1OralSolco Healthcare US, LLC2014-05-01Not applicableUs
LevetiracetamTablet, film coated250 mg/1OralMylan Institutional Inc.2008-11-04Not applicableUs
LevetiracetamTablet, film coated750 mg/1OralLupin Pharmaceuticals, Inc.2009-01-01Not applicableUs
LevetiracetamTablet, film coated750 mg/1OralLucid Pharma Llc2014-11-06Not applicableUs
LevetiracetamTablet1000 mg/1OralDr. Reddy's Laboratories Limited2009-01-15Not applicableUs
LevetiracetamTablet, film coated250 mg/1Oralbryant ranch prepack2009-01-01Not applicableUs
LevetiracetamTablet, film coated250 mg/1OralNorth Star Rx Llc2009-01-15Not applicableUs
LevetiracetamTablet, film coated, extended release750 mg/1OralApotex Corp.2011-09-12Not applicableUs
Levetiracetam AccordTablet, film coated250 mgOralAccord Healthcare Ltd2011-10-03Not applicableEu
Levetiracetam AccordTablet, film coated750 mgOralAccord Healthcare Ltd2011-10-03Not applicableEu
Levetiracetam AccordTablet, film coated500 mgOralAccord Healthcare Ltd2011-10-03Not applicableEu
Levetiracetam AccordTablet, film coated500 mgOralAccord Healthcare Ltd2011-10-03Not applicableEu
Levetiracetam AccordTablet, film coated1000 mgOralAccord Healthcare Ltd2011-10-03Not applicableEu
Levetiracetam AccordTablet, film coated250 mgOralAccord Healthcare Ltd2011-10-03Not applicableEu
Levetiracetam AccordTablet, film coated1000 mgOralAccord Healthcare Ltd2011-10-03Not applicableEu
Levetiracetam AccordTablet, film coated750 mgOralAccord Healthcare Ltd2011-10-03Not applicableEu
Levetiracetam AccordTablet, film coated750 mgOralAccord Healthcare Ltd2011-10-03Not applicableEu
Levetiracetam AccordTablet, film coated250 mgOralAccord Healthcare Ltd2011-10-03Not applicableEu
Levetiracetam AccordTablet, film coated250 mgOralAccord Healthcare Ltd2011-10-03Not applicableEu
Levetiracetam AccordTablet, film coated750 mgOralAccord Healthcare Ltd2011-10-03Not applicableEu
Levetiracetam AccordTablet, film coated500 mgOralAccord Healthcare Ltd2011-10-03Not applicableEu
Levetiracetam AccordTablet, film coated500 mgOralAccord Healthcare Ltd2011-10-03Not applicableEu
Levetiracetam AccordTablet, film coated1000 mgOralAccord Healthcare Ltd2011-10-03Not applicableEu
Levetiracetam AccordTablet, film coated500 mgOralAccord Healthcare Ltd2011-10-03Not applicableEu
Levetiracetam AccordTablet, film coated1000 mgOralAccord Healthcare Ltd2011-10-03Not applicableEu
Levetiracetam AccordTablet, film coated1000 mgOralAccord Healthcare Ltd2011-10-03Not applicableEu
Levetiracetam AccordTablet, film coated250 mgOralAccord Healthcare Ltd2011-10-03Not applicableEu
Levetiracetam AccordTablet, film coated750 mgOralAccord Healthcare Ltd2011-10-03Not applicableEu
Levetiracetam AccordTablet, film coated250 mgOralAccord Healthcare Ltd2011-10-03Not applicableEu
Levetiracetam AccordTablet, film coated750 mgOralAccord Healthcare Ltd2011-10-03Not applicableEu
Levetiracetam AccordTablet, film coated250 mgOralAccord Healthcare Ltd2011-10-03Not applicableEu
Levetiracetam AccordTablet, film coated750 mgOralAccord Healthcare Ltd2011-10-03Not applicableEu
Levetiracetam AccordTablet, film coated500 mgOralAccord Healthcare Ltd2011-10-03Not applicableEu
Levetiracetam AccordTablet, film coated1000 mgOralAccord Healthcare Ltd2011-10-03Not applicableEu
Levetiracetam AccordTablet, film coated500 mgOralAccord Healthcare Ltd2011-10-03Not applicableEu
Levetiracetam AccordTablet, film coated1000 mgOralAccord Healthcare Ltd2011-10-03Not applicableEu
Levetiracetam AccordTablet, film coated1000 mgOralAccord Healthcare Ltd2011-10-03Not applicableEu
Levetiracetam AccordTablet, film coated250 mgOralAccord Healthcare Ltd2011-10-03Not applicableEu
Levetiracetam AccordTablet, film coated750 mgOralAccord Healthcare Ltd2011-10-03Not applicableEu
Levetiracetam AccordTablet, film coated500 mgOralAccord Healthcare Ltd2011-10-03Not applicableEu
Levetiracetam AccordTablet, film coated250 mgOralAccord Healthcare Ltd2011-10-03Not applicableEu
Levetiracetam AccordTablet, film coated750 mgOralAccord Healthcare Ltd2011-10-03Not applicableEu
Levetiracetam AccordTablet, film coated750 mgOralAccord Healthcare Ltd2011-10-03Not applicableEu
Levetiracetam AccordTablet, film coated500 mgOralAccord Healthcare Ltd2011-10-03Not applicableEu
Levetiracetam AccordTablet, film coated250 mgOralAccord Healthcare Ltd2011-10-03Not applicableEu
Levetiracetam AccordTablet, film coated500 mgOralAccord Healthcare Ltd2011-10-03Not applicableEu
Levetiracetam AccordTablet, film coated1000 mgOralAccord Healthcare Ltd2011-10-03Not applicableEu
Levetiracetam AccordTablet, film coated1000 mgOralAccord Healthcare Ltd2011-10-03Not applicableEu
Levetiracetam ActavisTablet, film coated250 mgOralActavis Group Ptc Ehf2011-10-03Not applicableEu
Levetiracetam ActavisTablet, film coated750 mgOralActavis Group Ptc Ehf2011-10-03Not applicableEu
Levetiracetam ActavisTablet, film coated1000 mgOralActavis Group Ptc Ehf2011-10-03Not applicableEu
Levetiracetam ActavisTablet, film coated1000 mgOralActavis Group Ptc Ehf2011-10-03Not applicableEu
Levetiracetam ActavisTablet, film coated250 mgOralActavis Group Ptc Ehf2011-10-03Not applicableEu
Levetiracetam ActavisTablet, film coated500 mgOralActavis Group Ptc Ehf2011-10-03Not applicableEu
Levetiracetam ActavisTablet, film coated500 mgOralActavis Group Ptc Ehf2011-10-03Not applicableEu
Levetiracetam ActavisTablet, film coated750 mgOralActavis Group Ptc Ehf2011-10-03Not applicableEu
Levetiracetam ActavisTablet, film coated500 mgOralActavis Group Ptc Ehf2011-10-03Not applicableEu
Levetiracetam ActavisTablet, film coated250 mgOralActavis Group Ptc Ehf2011-10-03Not applicableEu
Levetiracetam ActavisTablet, film coated500 mgOralActavis Group Ptc Ehf2011-10-03Not applicableEu
Levetiracetam ActavisTablet, film coated1000 mgOralActavis Group Ptc Ehf2011-10-03Not applicableEu
Levetiracetam ActavisTablet, film coated750 mgOralActavis Group Ptc Ehf2011-10-03Not applicableEu
Levetiracetam ActavisTablet, film coated1000 mgOralActavis Group Ptc Ehf2011-10-03Not applicableEu
Levetiracetam ActavisTablet, film coated250 mgOralActavis Group Ptc Ehf2011-10-03Not applicableEu
Levetiracetam ActavisTablet, film coated250 mgOralActavis Group Ptc Ehf2011-10-03Not applicableEu
Levetiracetam ActavisTablet, film coated500 mgOralActavis Group Ptc Ehf2011-10-03Not applicableEu
Levetiracetam ActavisTablet, film coated1000 mgOralActavis Group Ptc Ehf2011-10-03Not applicableEu
Levetiracetam ActavisTablet, film coated500 mgOralActavis Group Ptc Ehf2011-10-03Not applicableEu
Levetiracetam ActavisTablet, film coated750 mgOralActavis Group Ptc Ehf2011-10-03Not applicableEu
Levetiracetam ActavisTablet, film coated1000 mgOralActavis Group Ptc Ehf2011-10-03Not applicableEu
Levetiracetam ActavisTablet, film coated250 mgOralActavis Group Ptc Ehf2011-10-03Not applicableEu
Levetiracetam ActavisTablet, film coated750 mgOralActavis Group Ptc Ehf2011-10-03Not applicableEu
Levetiracetam ActavisTablet, film coated1000 mgOralActavis Group Ptc Ehf2011-10-03Not applicableEu
Levetiracetam ActavisTablet, film coated250 mgOralActavis Group Ptc Ehf2011-10-03Not applicableEu
Levetiracetam ActavisTablet, film coated750 mgOralActavis Group Ptc Ehf2011-10-03Not applicableEu
Levetiracetam ActavisTablet, film coated1000 mgOralActavis Group Ptc Ehf2011-10-03Not applicableEu
Levetiracetam ActavisTablet, film coated250 mgOralActavis Group Ptc Ehf2011-10-03Not applicableEu
Levetiracetam ActavisTablet, film coated500 mgOralActavis Group Ptc Ehf2011-10-03Not applicableEu
Levetiracetam ActavisTablet, film coated1000 mgOralActavis Group Ptc Ehf2011-10-03Not applicableEu
Levetiracetam ActavisTablet, film coated500 mgOralActavis Group Ptc Ehf2011-10-03Not applicableEu
Levetiracetam ActavisTablet, film coated750 mgOralActavis Group Ptc Ehf2011-10-03Not applicableEu
Levetiracetam ActavisTablet, film coated250 mgOralActavis Group Ptc Ehf2011-10-03Not applicableEu
Levetiracetam ActavisTablet, film coated750 mgOralActavis Group Ptc Ehf2011-10-03Not applicableEu
Levetiracetam ActavisTablet, film coated1000 mgOralActavis Group Ptc Ehf2011-10-03Not applicableEu
Levetiracetam ActavisTablet, film coated500 mgOralActavis Group Ptc Ehf2011-10-03Not applicableEu
Levetiracetam ActavisTablet, film coated750 mgOralActavis Group Ptc Ehf2011-10-03Not applicableEu
Levetiracetam ActavisTablet, film coated250 mgOralActavis Group Ptc Ehf2011-10-03Not applicableEu
Levetiracetam ActavisTablet, film coated250 mgOralActavis Group Ptc Ehf2011-10-03Not applicableEu
Levetiracetam ActavisTablet, film coated500 mgOralActavis Group Ptc Ehf2011-10-03Not applicableEu
Levetiracetam ActavisTablet, film coated1000 mgOralActavis Group Ptc Ehf2011-10-03Not applicableEu
Levetiracetam ActavisTablet, film coated500 mgOralActavis Group Ptc Ehf2011-10-03Not applicableEu
Levetiracetam ActavisTablet, film coated750 mgOralActavis Group Ptc Ehf2011-10-03Not applicableEu
Levetiracetam Actavis GroupSolution100 mg/mlOralActavis Group Ptc Ehf2011-12-05Not applicableEu
Levetiracetam Actavis GroupSolution100 mg/mlOralActavis Group Ptc Ehf2011-12-05Not applicableEu
Levetiracetam Actavis GroupSolution100 mg/mlOralActavis Group Ptc Ehf2011-12-05Not applicableEu
Levetiracetam Extended-releaseTablet750 mg/1OralLotus Pharmaceutical Co., Ltd. Nantou Plant2016-10-31Not applicableUs
Levetiracetam Extended-releaseTablet, extended release500 mg/1OralNostrum Laboratories, Inc.2016-08-29Not applicableUs
Levetiracetam Extended-releaseTablet, extended release750 mg/1OralGolden State Medical Supply, Inc.2011-09-12Not applicableUs
Levetiracetam Extended-releaseTablet, film coated, extended release500 mg/1OralAnchen Pharmaceuticals, Inc.2011-10-04Not applicableUs
Levetiracetam Extended-releaseTablet500 mg/1OralLotus Pharmaceutical Co., Ltd. Nantou Plant2016-10-31Not applicableUs
Levetiracetam Extended-releaseTablet, extended release750 mg/1OralNostrum Laboratories, Inc.2016-08-29Not applicableUs
Levetiracetam Extended-releaseTablet, film coated, extended release750 mg/1OralAnchen Pharmaceuticals, Inc.2011-10-04Not applicableUs
Levetiracetam Extended-releaseTablet, extended release500 mg/1OralGolden State Medical Supply, Inc.2011-09-12Not applicableUs
Levetiracetam Hospira InfusionSolution, concentrate100 mg/mlIntravenousHospira Uk Limited2014-01-08Not applicableEu
Levetiracetam LevetiracetamSolution100 mg/mLOralCamber Pharmaceuticals, Inc.2015-06-11Not applicableUs
Levetiracetam SunInjection, solution, concentrate100 mg/mlIntravenousSun Pharmaceutical Industries Europe B.V.2011-12-14Not applicableEu
Levetiracetam TevaTablet, film coated250 mgOralTeva B.V.2011-08-26Not applicableEu
Levetiracetam TevaTablet, film coated750 mgOralTeva B.V.2011-08-26Not applicableEu
Levetiracetam TevaTablet, film coated500 mgOralTeva B.V.2011-08-26Not applicableEu
Levetiracetam TevaTablet, film coated1000 mgOralTeva B.V.2011-08-26Not applicableEu
Levetiracetam TevaTablet, film coated1000 mgOralTeva B.V.2011-08-26Not applicableEu
Levetiracetam TevaTablet, film coated500 mgOralTeva B.V.2011-08-26Not applicableEu
Levetiracetam TevaTablet, film coated750 mgOralTeva B.V.2011-08-26Not applicableEu
Levetiracetam TevaTablet, film coated1000 mgOralTeva B.V.2011-08-26Not applicableEu
Levetiracetam TevaTablet, film coated250 mgOralTeva B.V.2011-08-26Not applicableEu
Levetiracetam TevaTablet, film coated250 mgOralTeva B.V.2011-08-26Not applicableEu
Levetiracetam TevaTablet, film coated750 mgOralTeva B.V.2011-08-26Not applicableEu
Levetiracetam TevaTablet, film coated500 mgOralTeva B.V.2011-08-26Not applicableEu
Levetiracetam TevaTablet, film coated250 mgOralTeva B.V.2011-08-26Not applicableEu
Levetiracetam TevaTablet, film coated1000 mgOralTeva B.V.2011-08-26Not applicableEu
Levetiracetam TevaTablet, film coated500 mgOralTeva B.V.2011-08-26Not applicableEu
Levetiracetam TevaTablet, film coated750 mgOralTeva B.V.2011-08-26Not applicableEu
Levetiracetam TevaTablet, film coated250 mgOralTeva B.V.2011-08-26Not applicableEu
Levetiracetam TevaTablet, film coated1000 mgOralTeva B.V.2011-08-26Not applicableEu
Levetiracetam TevaTablet, film coated250 mgOralTeva B.V.2011-08-26Not applicableEu
Levetiracetam TevaTablet, film coated750 mgOralTeva B.V.2011-08-26Not applicableEu
Levetiracetam TevaTablet, film coated500 mgOralTeva B.V.2011-08-26Not applicableEu
Levetiracetam TevaTablet, film coated1000 mgOralTeva B.V.2011-08-26Not applicableEu
Levetiracetam TevaTablet, film coated500 mgOralTeva B.V.2011-08-26Not applicableEu
Levetiracetam TevaTablet, film coated750 mgOralTeva B.V.2011-08-26Not applicableEu
Levetiracetam TevaTablet, film coated250 mgOralTeva B.V.2011-08-26Not applicableEu
Levetiracetam TevaTablet, film coated1000 mgOralTeva B.V.2011-08-26Not applicableEu
Levetiracetam TevaTablet, film coated500 mgOralTeva B.V.2011-08-26Not applicableEu
Levetiracetam TevaTablet, film coated750 mgOralTeva B.V.2011-08-26Not applicableEu
Levetiracetam TevaTablet, film coated750 mgOralTeva B.V.2011-08-26Not applicableEu
Levetiracetam TevaTablet, film coated250 mgOralTeva B.V.2011-08-26Not applicableEu
Levetiracetam TevaTablet, film coated1000 mgOralTeva B.V.2011-08-26Not applicableEu
Levetiracetam TevaTablet, film coated500 mgOralTeva B.V.2011-08-26Not applicableEu
LevetiractamTablet250 mg/1OralREMEDYREPACK INC.2011-11-07Not applicableUs
MateverTablet, film coated250 mgOralPharmathen S.A.2011-10-03Not applicableEu
MateverTablet, film coated750 mgOralPharmathen S.A.2011-10-03Not applicableEu
MateverTablet, film coated500 mgOralPharmathen S.A.2011-10-03Not applicableEu
MateverTablet, film coated1000 mgOralPharmathen S.A.2011-10-03Not applicableEu
MateverTablet, film coated500 mgOralPharmathen S.A.2011-10-03Not applicableEu
MateverTablet, film coated750 mgOralPharmathen S.A.2011-10-03Not applicableEu
MateverTablet, film coated750 mgOralPharmathen S.A.2011-10-03Not applicableEu
MateverInjection, solution, concentrate100 mg/mlIntravenousPharmathen S.A.2011-10-03Not applicableEu
MateverTablet, film coated250 mgOralPharmathen S.A.2011-10-03Not applicableEu
MateverTablet, film coated750 mgOralPharmathen S.A.2011-10-03Not applicableEu
MateverTablet, film coated500 mgOralPharmathen S.A.2011-10-03Not applicableEu
MateverTablet, film coated1000 mgOralPharmathen S.A.2011-10-03Not applicableEu
MateverTablet, film coated500 mgOralPharmathen S.A.2011-10-03Not applicableEu
MateverTablet, film coated1000 mgOralPharmathen S.A.2011-10-03Not applicableEu
MateverTablet, film coated250 mgOralPharmathen S.A.2011-10-03Not applicableEu
MateverTablet, film coated750 mgOralPharmathen S.A.2011-10-03Not applicableEu
MateverTablet, film coated250 mgOralPharmathen S.A.2011-10-03Not applicableEu
MateverTablet, film coated750 mgOralPharmathen S.A.2011-10-03Not applicableEu
MateverTablet, film coated500 mgOralPharmathen S.A.2011-10-03Not applicableEu
MateverTablet, film coated1000 mgOralPharmathen S.A.2011-10-03Not applicableEu
MateverTablet, film coated500 mgOralPharmathen S.A.2011-10-03Not applicableEu
MateverTablet, film coated1000 mgOralPharmathen S.A.2011-10-03Not applicableEu
MateverTablet, film coated250 mgOralPharmathen S.A.2011-10-03Not applicableEu
MateverTablet, film coated750 mgOralPharmathen S.A.2011-10-03Not applicableEu
MateverTablet, film coated250 mgOralPharmathen S.A.2011-10-03Not applicableEu
MateverTablet, film coated750 mgOralPharmathen S.A.2011-10-03Not applicableEu
MateverTablet, film coated500 mgOralPharmathen S.A.2011-10-03Not applicableEu
MateverTablet, film coated1000 mgOralPharmathen S.A.2011-10-03Not applicableEu
MateverTablet, film coated500 mgOralPharmathen S.A.2011-10-03Not applicableEu
MateverTablet, film coated1000 mgOralPharmathen S.A.2011-10-03Not applicableEu
RoweepraTablet, film coated500 mg/1OralOwp Pharmaceuticals, Inc.2016-01-11Not applicableUs
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International BrandsNot Available
Brand mixturesNot Available
SaltsNot Available
Categories
UNII44YRR34555
CAS number102767-28-2
WeightAverage: 170.212
Monoisotopic: 170.105527699
Chemical FormulaC8H14N2O2
InChI KeyHPHUVLMMVZITSG-LURJTMIESA-N
InChI
InChI=1S/C8H14N2O2/c1-2-6(8(9)12)10-5-3-4-7(10)11/h6H,2-5H2,1H3,(H2,9,12)/t6-/m0/s1
IUPAC Name
(2S)-2-(2-oxopyrrolidin-1-yl)butanamide
SMILES
CC[[email protected]](N1CCCC1=O)C(N)=O
Pharmacology
IndicationUsed as adjunctive therapy in the treatment of partial onset seizures in adults and children 4 years of age and older with epilepsy.
Structured Indications
PharmacodynamicsNot Available
Mechanism of actionThe precise mechanism(s) by which levetiracetam exerts its antiepileptic effect is unknown. The antiepileptic activity of levetiracetam was assessed in a number of animal models of epileptic seizures. Levetiracetam did not inhibit single seizures induced by maximal stimulation with electrical current or different chemoconvulsants and showed only minimal activity in submaximal stimulation and in threshold tests. Protection was observed, however, against secondarily generalized activity from focal seizures induced by pilocarpine and kainic acid, two chemoconvulsants that induce seizures that mimic some features of human complex partial seizures with secondary generalization. Levetiracetam also displayed inhibitory properties in the kindling model in rats, another model of human complex partial seizures, both during kindling development and in the fully kindled state. The predictive value of these animal models for specific types of human epilepsy is uncertain. Levetiracetam is thought to stimulate synaptic vesicle protein 2A (SV2A), inhibiting neurotransmitter release.
TargetKindPharmacological actionActionsOrganismUniProt ID
Synaptic vesicle glycoprotein 2AProteinyes
agonist
HumanQ7L0J3 details
Voltage-dependent N-type calcium channel subunit alpha-1BProteinyes
inhibitor
HumanQ00975 details
Related Articles
AbsorptionRapidly and almost completely absorbed after oral administration (99%). Peak plasma concentrations occurring in about an hour following oral administration in fasted subjects.
Volume of distributionNot Available
Protein bindingVery low (<10%)
Metabolism

The major metabolic pathway of levetiracetam (24% of dose) is an enzymatic hydrolysis of the acetamide group. No CYP450 metabolism detected.

Route of eliminationSixty-six percent (66%) of the dose is renally excreted unchanged. The metabolites have no known pharmacological activity and are renally excreted. The mechanism of excretion is glomerular filtration with subsequent partial tubular reabsorption.
Half life6-8 hours
Clearance
  • 0.96 mL/min/kg
ToxicitySide effects include aggression, agitation, coma, drowsiness, reduced consciousness, slowed breathing
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
Interactions
Drug Interactions
DrugInteractionDrug group
1,1,1,2 TetrafluoroethaneThe risk or severity of adverse effects can be increased when Levetiracetam is combined with 1,1,1,2 Tetrafluoroethane.Investigational
7-NitroindazoleThe risk or severity of adverse effects can be increased when 7-Nitroindazole is combined with Levetiracetam.Experimental
AcepromazineThe risk or severity of adverse effects can be increased when Acepromazine is combined with Levetiracetam.Approved, Vet Approved
AceprometazineThe risk or severity of adverse effects can be increased when Aceprometazine is combined with Levetiracetam.Approved
AcetaminophenThe serum concentration of Levetiracetam can be increased when it is combined with Acetaminophen.Approved
adipiplonThe risk or severity of adverse effects can be increased when adipiplon is combined with Levetiracetam.Investigational
AfatinibThe serum concentration of Levetiracetam can be increased when it is combined with Afatinib.Approved
AgomelatineThe risk or severity of adverse effects can be increased when Agomelatine is combined with Levetiracetam.Approved, Investigational
AlbendazoleThe serum concentration of Levetiracetam can be increased when it is combined with Albendazole.Approved, Vet Approved
AldosteroneThe serum concentration of Levetiracetam can be decreased when it is combined with Aldosterone.Experimental
AlectinibThe serum concentration of Levetiracetam can be increased when it is combined with Alectinib.Approved
AlfaxaloneThe risk or severity of adverse effects can be increased when Alfaxalone is combined with Levetiracetam.Vet Approved
AlfentanilThe serum concentration of Levetiracetam can be increased when it is combined with Alfentanil.Approved, Illicit
AlphacetylmethadolThe risk or severity of adverse effects can be increased when Alphacetylmethadol is combined with Levetiracetam.Experimental, Illicit
AlprazolamThe risk or severity of adverse effects can be increased when Alprazolam is combined with Levetiracetam.Approved, Illicit, Investigational
AmantadineThe serum concentration of Levetiracetam can be increased when it is combined with Amantadine.Approved
Aminohippuric acidThe serum concentration of Levetiracetam can be increased when it is combined with Aminohippuric acid.Approved
AmiodaroneThe serum concentration of Levetiracetam can be decreased when it is combined with Amiodarone.Approved, Investigational
AmisulprideThe risk or severity of adverse effects can be increased when Amisulpride is combined with Levetiracetam.Approved, Investigational
AmitriptylineThe serum concentration of Levetiracetam can be increased when it is combined with Amitriptyline.Approved
AmlodipineThe serum concentration of Levetiracetam can be increased when it is combined with Amlodipine.Approved
AmobarbitalThe risk or severity of adverse effects can be increased when Amobarbital is combined with Levetiracetam.Approved, Illicit
AmoxapineThe risk or severity of adverse effects can be increased when Amoxapine is combined with Levetiracetam.Approved
AmperozideThe risk or severity of adverse effects can be increased when Amperozide is combined with Levetiracetam.Experimental
AmprenavirThe serum concentration of Levetiracetam can be decreased when it is combined with Amprenavir.Approved
AmsacrineThe serum concentration of Levetiracetam can be increased when it is combined with Amsacrine.Approved
AripiprazoleThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Levetiracetam.Approved, Investigational
ArticaineThe risk or severity of adverse effects can be increased when Articaine is combined with Levetiracetam.Approved
AsenapineThe risk or severity of adverse effects can be increased when Asenapine is combined with Levetiracetam.Approved
AstemizoleThe serum concentration of Levetiracetam can be increased when it is combined with Astemizole.Approved, Withdrawn
AtazanavirThe serum concentration of Levetiracetam can be increased when it is combined with Atazanavir.Approved, Investigational
AtenololThe serum concentration of Levetiracetam can be increased when it is combined with Atenolol.Approved
AtorvastatinThe serum concentration of Levetiracetam can be increased when it is combined with Atorvastatin.Approved
AzaperoneThe risk or severity of adverse effects can be increased when Azaperone is combined with Levetiracetam.Vet Approved
AzelastineLevetiracetam may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved
AzelastineThe serum concentration of Levetiracetam can be increased when it is combined with Azelastine.Approved
AzithromycinThe serum concentration of Levetiracetam can be increased when it is combined with Azithromycin.Approved
BaclofenThe risk or severity of adverse effects can be increased when Baclofen is combined with Levetiracetam.Approved
BarbitalThe risk or severity of adverse effects can be increased when Barbital is combined with Levetiracetam.Illicit
BenperidolThe risk or severity of adverse effects can be increased when Levetiracetam is combined with Benperidol.Investigational
BenzocaineThe serum concentration of Levetiracetam can be increased when it is combined with Benzocaine.Approved
Benzyl alcoholThe risk or severity of adverse effects can be increased when Benzyl alcohol is combined with Levetiracetam.Approved
BepridilThe serum concentration of Levetiracetam can be increased when it is combined with Bepridil.Approved, Withdrawn
BiperidenThe serum concentration of Levetiracetam can be increased when it is combined with Biperiden.Approved
BosutinibThe serum concentration of Levetiracetam can be increased when it is combined with Bosutinib.Approved
BrexpiprazoleThe risk or severity of adverse effects can be increased when Levetiracetam is combined with Brexpiprazole.Approved
BrimonidineThe risk or severity of adverse effects can be increased when Brimonidine is combined with Levetiracetam.Approved
BrimonidineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Levetiracetam.Approved
BromazepamThe risk or severity of adverse effects can be increased when Bromazepam is combined with Levetiracetam.Approved, Illicit
BromocriptineThe serum concentration of Levetiracetam can be increased when it is combined with Bromocriptine.Approved, Investigational
BrompheniramineThe risk or severity of adverse effects can be increased when Brompheniramine is combined with Levetiracetam.Approved
BrotizolamThe risk or severity of adverse effects can be increased when Brotizolam is combined with Levetiracetam.Approved, Withdrawn
BupivacaineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Levetiracetam.Approved, Investigational
BuprenorphineLevetiracetam may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.Approved, Illicit, Investigational, Vet Approved
BuspironeThe serum concentration of Levetiracetam can be increased when it is combined with Buspirone.Approved, Investigational
ButabarbitalThe risk or severity of adverse effects can be increased when Butabarbital is combined with Levetiracetam.Approved, Illicit
ButacaineThe risk or severity of adverse effects can be increased when Butacaine is combined with Levetiracetam.Vet Approved
ButalbitalThe risk or severity of adverse effects can be increased when Butalbital is combined with Levetiracetam.Approved, Illicit
ButambenThe risk or severity of adverse effects can be increased when Butamben is combined with Levetiracetam.Approved
ButethalThe risk or severity of adverse effects can be increased when Butethal is combined with Levetiracetam.Approved, Illicit
ButorphanolThe risk or severity of adverse effects can be increased when Butorphanol is combined with Levetiracetam.Approved, Illicit, Vet Approved
CabazitaxelThe serum concentration of Levetiracetam can be increased when it is combined with Cabazitaxel.Approved
CaffeineThe serum concentration of Levetiracetam can be increased when it is combined with Caffeine.Approved
CanagliflozinThe serum concentration of Levetiracetam can be increased when it is combined with Canagliflozin.Approved
CandesartanThe serum concentration of Levetiracetam can be increased when it is combined with Candesartan.Approved
CaptoprilThe serum concentration of Levetiracetam can be increased when it is combined with Captopril.Approved
CarbamazepineThe serum concentration of Levetiracetam can be decreased when it is combined with Carbamazepine.Approved, Investigational
CarbinoxamineThe risk or severity of adverse effects can be increased when Carbinoxamine is combined with Levetiracetam.Approved
CarfentanilThe risk or severity of adverse effects can be increased when Carfentanil is combined with Levetiracetam.Illicit, Vet Approved
CarisoprodolThe risk or severity of adverse effects can be increased when Carisoprodol is combined with Levetiracetam.Approved
CarvedilolThe serum concentration of Levetiracetam can be increased when it is combined with Carvedilol.Approved, Investigational
CaspofunginThe serum concentration of Levetiracetam can be increased when it is combined with Caspofungin.Approved
CetirizineThe risk or severity of adverse effects can be increased when Cetirizine is combined with Levetiracetam.Approved
Chloral hydrateThe risk or severity of adverse effects can be increased when Chloral hydrate is combined with Levetiracetam.Approved, Illicit, Vet Approved
ChlordiazepoxideThe risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Levetiracetam.Approved, Illicit
ChlormezanoneThe risk or severity of adverse effects can be increased when Chlormezanone is combined with Levetiracetam.Approved, Withdrawn
ChloroprocaineThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with Levetiracetam.Approved
ChloroquineThe serum concentration of Levetiracetam can be increased when it is combined with Chloroquine.Approved, Vet Approved
ChlorphenamineThe risk or severity of adverse effects can be increased when Chlorphenamine is combined with Levetiracetam.Approved
ChlorpromazineThe serum concentration of Levetiracetam can be increased when it is combined with Chlorpromazine.Approved, Vet Approved
ChlorpropamideThe serum concentration of Levetiracetam can be increased when it is combined with Chlorpropamide.Approved
ChlorprothixeneThe serum concentration of Levetiracetam can be increased when it is combined with Chlorprothixene.Approved, Withdrawn
ChlorzoxazoneThe risk or severity of adverse effects can be increased when Chlorzoxazone is combined with Levetiracetam.Approved
CholesterolThe serum concentration of Levetiracetam can be increased when it is combined with Cholesterol.Experimental
Cholic AcidThe serum concentration of Levetiracetam can be decreased when it is combined with Cholic Acid.Approved
CilazaprilThe serum concentration of Levetiracetam can be increased when it is combined with Cilazapril.Approved
CimetidineThe serum concentration of Levetiracetam can be decreased when it is combined with Cimetidine.Approved
CinchocaineThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Levetiracetam.Approved, Vet Approved
CiprofloxacinThe serum concentration of Levetiracetam can be increased when it is combined with Ciprofloxacin.Approved, Investigational
CitalopramThe serum concentration of Levetiracetam can be increased when it is combined with Citalopram.Approved
ClarithromycinThe serum concentration of Levetiracetam can be increased when it is combined with Clarithromycin.Approved
ClemastineThe risk or severity of adverse effects can be increased when Clemastine is combined with Levetiracetam.Approved
ClidiniumThe risk or severity of adverse effects can be increased when Clidinium is combined with Levetiracetam.Approved
ClobazamThe risk or severity of adverse effects can be increased when Clobazam is combined with Levetiracetam.Approved, Illicit
ClofazimineThe serum concentration of Levetiracetam can be increased when it is combined with Clofazimine.Approved, Investigational
clomethiazoleThe risk or severity of adverse effects can be increased when clomethiazole is combined with Levetiracetam.Investigational
ClomipramineThe serum concentration of Levetiracetam can be increased when it is combined with Clomipramine.Approved, Vet Approved
ClonazepamThe risk or severity of adverse effects can be increased when Clonazepam is combined with Levetiracetam.Approved, Illicit
ClonidineThe risk or severity of adverse effects can be increased when Clonidine is combined with Levetiracetam.Approved
ClorazepateThe risk or severity of adverse effects can be increased when Clorazepate is combined with Levetiracetam.Approved, Illicit
ClotrimazoleThe serum concentration of Levetiracetam can be decreased when it is combined with Clotrimazole.Approved, Vet Approved
ClozapineThe risk or severity of adverse effects can be increased when Clozapine is combined with Levetiracetam.Approved
CobicistatThe serum concentration of Levetiracetam can be increased when it is combined with Cobicistat.Approved
CocaineThe risk or severity of adverse effects can be increased when Cocaine is combined with Levetiracetam.Approved, Illicit
CodeineThe risk or severity of adverse effects can be increased when Codeine is combined with Levetiracetam.Approved, Illicit
ColchicineThe serum concentration of Levetiracetam can be increased when it is combined with Colchicine.Approved
ColforsinThe serum concentration of Levetiracetam can be increased when it is combined with Colforsin.Experimental
CrizotinibThe serum concentration of Levetiracetam can be increased when it is combined with Crizotinib.Approved
CyclizineThe risk or severity of adverse effects can be increased when Cyclizine is combined with Levetiracetam.Approved
CyclobenzaprineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Levetiracetam.Approved
CyclophosphamideThe serum concentration of Levetiracetam can be increased when it is combined with Cyclophosphamide.Approved, Investigational
CyclosporineThe serum concentration of Levetiracetam can be decreased when it is combined with Cyclosporine.Approved, Investigational, Vet Approved
CyproheptadineThe risk or severity of adverse effects can be increased when Cyproheptadine is combined with Levetiracetam.Approved
DaclatasvirThe serum concentration of Levetiracetam can be increased when it is combined with Daclatasvir.Approved
DactinomycinThe serum concentration of Levetiracetam can be increased when it is combined with Dactinomycin.Approved
DantroleneThe risk or severity of adverse effects can be increased when Levetiracetam is combined with Dantrolene.Approved
DapiprazoleThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Levetiracetam.Approved
DapoxetineThe risk or severity of adverse effects can be increased when Levetiracetam is combined with Dapoxetine.Investigational
DasatinibThe serum concentration of Levetiracetam can be increased when it is combined with Dasatinib.Approved, Investigational
DaunorubicinThe serum concentration of Levetiracetam can be decreased when it is combined with Daunorubicin.Approved
deramciclaneThe risk or severity of adverse effects can be increased when deramciclane is combined with Levetiracetam.Investigational
DesfluraneThe risk or severity of adverse effects can be increased when Desflurane is combined with Levetiracetam.Approved
DesipramineThe serum concentration of Levetiracetam can be increased when it is combined with Desipramine.Approved
DesloratadineThe serum concentration of Levetiracetam can be increased when it is combined with Desloratadine.Approved, Investigational
DesvenlafaxineThe risk or severity of adverse effects can be increased when Levetiracetam is combined with Desvenlafaxine.Approved
DetomidineThe risk or severity of adverse effects can be increased when Detomidine is combined with Levetiracetam.Vet Approved
DexamethasoneThe serum concentration of Levetiracetam can be decreased when it is combined with Dexamethasone.Approved, Investigational, Vet Approved
DexbrompheniramineThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Levetiracetam.Approved
DexmedetomidineThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Levetiracetam.Approved, Vet Approved
DextromethorphanThe serum concentration of Levetiracetam can be increased when it is combined with Dextromethorphan.Approved
DextromoramideThe risk or severity of adverse effects can be increased when Dextromoramide is combined with Levetiracetam.Experimental, Illicit
DextropropoxypheneThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Levetiracetam.Approved, Illicit, Withdrawn
DezocineThe risk or severity of adverse effects can be increased when Dezocine is combined with Levetiracetam.Approved
DiazepamThe risk or severity of adverse effects can be increased when Diazepam is combined with Levetiracetam.Approved, Illicit, Vet Approved
DiclofenacThe serum concentration of Levetiracetam can be increased when it is combined with Diclofenac.Approved, Vet Approved
DifenoxinThe risk or severity of adverse effects can be increased when Levetiracetam is combined with Difenoxin.Approved, Illicit
DigoxinThe serum concentration of Levetiracetam can be decreased when it is combined with Digoxin.Approved
DihydrocodeineThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Levetiracetam.Approved, Illicit
DihydroergotamineThe serum concentration of Levetiracetam can be increased when it is combined with Dihydroergotamine.Approved
DihydroetorphineThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Levetiracetam.Experimental, Illicit
DihydromorphineThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Levetiracetam.Experimental, Illicit
DiltiazemThe serum concentration of Levetiracetam can be increased when it is combined with Diltiazem.Approved
DimenhydrinateThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Levetiracetam.Approved
DiphenhydramineThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Levetiracetam.Approved
DiphenoxylateThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Levetiracetam.Approved, Illicit
DipyridamoleThe serum concentration of Levetiracetam can be increased when it is combined with Dipyridamole.Approved
DoramectinThe risk or severity of adverse effects can be increased when Doramectin is combined with Levetiracetam.Vet Approved
DoxazosinThe serum concentration of Levetiracetam can be increased when it is combined with Doxazosin.Approved
DoxepinThe serum concentration of Levetiracetam can be increased when it is combined with Doxepin.Approved
DoxorubicinThe serum concentration of Levetiracetam can be decreased when it is combined with Doxorubicin.Approved, Investigational
DoxylamineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Levetiracetam.Approved, Vet Approved
DPDPEThe risk or severity of adverse effects can be increased when DPDPE is combined with Levetiracetam.Investigational
DronabinolDronabinol may increase the central nervous system depressant (CNS depressant) activities of Levetiracetam.Approved, Illicit
DronedaroneThe serum concentration of Levetiracetam can be increased when it is combined with Dronedarone.Approved
DroperidolDroperidol may increase the central nervous system depressant (CNS depressant) activities of Levetiracetam.Approved, Vet Approved
DrotebanolThe risk or severity of adverse effects can be increased when Drotebanol is combined with Levetiracetam.Experimental, Illicit
DuloxetineThe risk or severity of adverse effects can be increased when Levetiracetam is combined with Duloxetine.Approved
DyclonineThe risk or severity of adverse effects can be increased when Dyclonine is combined with Levetiracetam.Approved
EcgonineThe risk or severity of adverse effects can be increased when Ecgonine is combined with Levetiracetam.Experimental, Illicit
ECGONINE METHYL ESTERThe risk or severity of adverse effects can be increased when ECGONINE METHYL ESTER is combined with Levetiracetam.Experimental
EcopipamThe risk or severity of adverse effects can be increased when Levetiracetam is combined with Ecopipam.Investigational
EfavirenzThe risk or severity of adverse effects can be increased when Efavirenz is combined with Levetiracetam.Approved, Investigational
ElbasvirThe serum concentration of Levetiracetam can be increased when it is combined with Elbasvir.Approved
EnalaprilThe serum concentration of Levetiracetam can be increased when it is combined with Enalapril.Approved, Vet Approved
EnfluraneThe risk or severity of adverse effects can be increased when Enflurane is combined with Levetiracetam.Approved, Vet Approved
EntacaponeThe risk or severity of adverse effects can be increased when Entacapone is combined with Levetiracetam.Approved, Investigational
EnzalutamideThe serum concentration of Levetiracetam can be increased when it is combined with Enzalutamide.Approved
ErgonovineThe serum concentration of Levetiracetam can be increased when it is combined with Ergonovine.Approved
ErgotamineThe serum concentration of Levetiracetam can be increased when it is combined with Ergotamine.Approved
ErythromycinThe serum concentration of Levetiracetam can be decreased when it is combined with Erythromycin.Approved, Vet Approved
EscitalopramThe risk or severity of adverse effects can be increased when Levetiracetam is combined with Escitalopram.Approved, Investigational
EstazolamThe risk or severity of adverse effects can be increased when Estazolam is combined with Levetiracetam.Approved, Illicit
EstramustineThe serum concentration of Levetiracetam can be increased when it is combined with Estramustine.Approved
EstriolThe serum concentration of Levetiracetam can be decreased when it is combined with Estriol.Approved, Vet Approved
EstroneThe serum concentration of Levetiracetam can be decreased when it is combined with Estrone.Approved
EszopicloneThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Levetiracetam.Approved
EthanolLevetiracetam may increase the central nervous system depressant (CNS depressant) activities of Ethanol.Approved
EthchlorvynolThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Levetiracetam.Approved, Illicit, Withdrawn
EthosuximideThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Levetiracetam.Approved
EthotoinThe risk or severity of adverse effects can be increased when Ethotoin is combined with Levetiracetam.Approved
Ethyl carbamateThe risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Levetiracetam.Withdrawn
Ethyl loflazepateThe risk or severity of adverse effects can be increased when Ethyl loflazepate is combined with Levetiracetam.Approved, Illicit
EthylmorphineThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Levetiracetam.Approved, Illicit
EtidocaineThe risk or severity of adverse effects can be increased when Etidocaine is combined with Levetiracetam.Approved
EtifoxineThe risk or severity of adverse effects can be increased when Etifoxine is combined with Levetiracetam.Withdrawn
EtizolamThe risk or severity of adverse effects can be increased when Etizolam is combined with Levetiracetam.Approved
EtomidateThe risk or severity of adverse effects can be increased when Etomidate is combined with Levetiracetam.Approved
EtoperidoneThe risk or severity of adverse effects can be increased when Levetiracetam is combined with Etoperidone.Approved
EtoposideThe serum concentration of Levetiracetam can be increased when it is combined with Etoposide.Approved
EtorphineThe risk or severity of adverse effects can be increased when Etorphine is combined with Levetiracetam.Illicit, Vet Approved
EtravirineThe serum concentration of Levetiracetam can be increased when it is combined with Etravirine.Approved
EzogabineThe risk or severity of adverse effects can be increased when Levetiracetam is combined with Ezogabine.Approved
FelbamateThe risk or severity of adverse effects can be increased when Felbamate is combined with Levetiracetam.Approved
FelodipineThe serum concentration of Levetiracetam can be increased when it is combined with Felodipine.Approved, Investigational
FencamfamineThe risk or severity of adverse effects can be increased when Fencamfamine is combined with Levetiracetam.Approved, Illicit, Withdrawn
FentanylThe serum concentration of Levetiracetam can be increased when it is combined with Fentanyl.Approved, Illicit, Investigational, Vet Approved
FexofenadineThe serum concentration of Levetiracetam can be increased when it is combined with Fexofenadine.Approved
FidaxomicinThe serum concentration of Levetiracetam can be increased when it is combined with Fidaxomicin.Approved
FlibanserinThe risk or severity of adverse effects can be increased when Levetiracetam is combined with Flibanserin.Approved
FluconazoleThe serum concentration of Levetiracetam can be increased when it is combined with Fluconazole.Approved
FludiazepamThe risk or severity of adverse effects can be increased when Fludiazepam is combined with Levetiracetam.Approved, Illicit
FlunarizineThe risk or severity of adverse effects can be increased when Levetiracetam is combined with Flunarizine.Approved
FlunitrazepamThe risk or severity of adverse effects can be increased when Flunitrazepam is combined with Levetiracetam.Approved, Illicit
FluoxetineThe serum concentration of Levetiracetam can be increased when it is combined with Fluoxetine.Approved, Vet Approved
FlupentixolThe serum concentration of Levetiracetam can be increased when it is combined with Flupentixol.Approved, Withdrawn
FluphenazineThe serum concentration of Levetiracetam can be increased when it is combined with Fluphenazine.Approved
FlurazepamThe serum concentration of Levetiracetam can be increased when it is combined with Flurazepam.Approved, Illicit
FluspirileneThe risk or severity of adverse effects can be increased when Fluspirilene is combined with Levetiracetam.Approved
Fluticasone PropionateThe risk or severity of adverse effects can be increased when Fluticasone Propionate is combined with Levetiracetam.Approved
FluvoxamineThe serum concentration of Levetiracetam can be increased when it is combined with Fluvoxamine.Approved, Investigational
FosphenytoinThe risk or severity of adverse effects can be increased when Levetiracetam is combined with Fosphenytoin.Approved
FospropofolThe risk or severity of adverse effects can be increased when Fospropofol is combined with Levetiracetam.Approved, Illicit
GabapentinThe risk or severity of adverse effects can be increased when Gabapentin is combined with Levetiracetam.Approved, Investigational
gabapentin enacarbilThe risk or severity of adverse effects can be increased when Levetiracetam is combined with gabapentin enacarbil.Approved
Gamma Hydroxybutyric AcidThe risk or severity of adverse effects can be increased when Gamma Hydroxybutyric Acid is combined with Levetiracetam.Approved, Illicit
GefitinibThe serum concentration of Levetiracetam can be increased when it is combined with Gefitinib.Approved, Investigational
GenisteinThe serum concentration of Levetiracetam can be increased when it is combined with Genistein.Investigational
GepironeThe risk or severity of adverse effects can be increased when Levetiracetam is combined with Gepirone.Investigational
GlutethimideThe risk or severity of adverse effects can be increased when Glutethimide is combined with Levetiracetam.Approved, Illicit
GlyburideThe serum concentration of Levetiracetam can be increased when it is combined with Glyburide.Approved
GlycerolThe serum concentration of Levetiracetam can be increased when it is combined with Glycerol.Experimental
Gramicidin DThe serum concentration of Levetiracetam can be increased when it is combined with Gramicidin D.Approved
GrepafloxacinThe serum concentration of Levetiracetam can be increased when it is combined with Grepafloxacin.Withdrawn
GuanfacineThe risk or severity of adverse effects can be increased when Guanfacine is combined with Levetiracetam.Approved, Investigational
HalazepamThe risk or severity of adverse effects can be increased when Halazepam is combined with Levetiracetam.Approved, Illicit, Withdrawn
HaloperidolThe serum concentration of Levetiracetam can be increased when it is combined with Haloperidol.Approved
HalothaneThe risk or severity of adverse effects can be increased when Halothane is combined with Levetiracetam.Approved, Vet Approved
HeroinThe risk or severity of adverse effects can be increased when Heroin is combined with Levetiracetam.Approved, Illicit
HexobarbitalThe risk or severity of adverse effects can be increased when Hexobarbital is combined with Levetiracetam.Approved
HydrocodoneLevetiracetam may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Illicit
HydrocortisoneThe serum concentration of Levetiracetam can be increased when it is combined with Hydrocortisone.Approved, Vet Approved
HydromorphoneThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Levetiracetam.Approved, Illicit
HydroxyzineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Levetiracetam.Approved
IdelalisibThe serum concentration of Levetiracetam can be increased when it is combined with Idelalisib.Approved
IloperidoneThe risk or severity of adverse effects can be increased when Levetiracetam is combined with Iloperidone.Approved
ImatinibThe serum concentration of Levetiracetam can be increased when it is combined with Imatinib.Approved
ImipramineThe serum concentration of Levetiracetam can be increased when it is combined with Imipramine.Approved
IndalpineThe risk or severity of adverse effects can be increased when Levetiracetam is combined with Indalpine.Investigational, Withdrawn
IndinavirThe serum concentration of Levetiracetam can be decreased when it is combined with Indinavir.Approved
IndomethacinThe serum concentration of Levetiracetam can be increased when it is combined with Indomethacin.Approved, Investigational
IsavuconazoniumThe serum concentration of Levetiracetam can be increased when it is combined with Isavuconazonium.Approved, Investigational
IsofluraneThe risk or severity of adverse effects can be increased when Isoflurane is combined with Levetiracetam.Approved, Vet Approved
ItraconazoleThe serum concentration of Levetiracetam can be increased when it is combined with Itraconazole.Approved, Investigational
IvacaftorThe serum concentration of Levetiracetam can be increased when it is combined with Ivacaftor.Approved
IvermectinThe serum concentration of Levetiracetam can be increased when it is combined with Ivermectin.Approved, Vet Approved
KetamineThe serum concentration of Levetiracetam can be increased when it is combined with Ketamine.Approved, Vet Approved
KetazolamThe risk or severity of adverse effects can be increased when Ketazolam is combined with Levetiracetam.Approved
KetobemidoneThe risk or severity of adverse effects can be increased when Ketobemidone is combined with Levetiracetam.Approved
KetoconazoleThe serum concentration of Levetiracetam can be increased when it is combined with Ketoconazole.Approved, Investigational
LamotrigineThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Levetiracetam.Approved, Investigational
LansoprazoleThe serum concentration of Levetiracetam can be increased when it is combined with Lansoprazole.Approved, Investigational
LapatinibThe serum concentration of Levetiracetam can be increased when it is combined with Lapatinib.Approved, Investigational
LevobupivacaineThe risk or severity of adverse effects can be increased when Levobupivacaine is combined with Levetiracetam.Approved
LevocabastineThe risk or severity of adverse effects can be increased when Levetiracetam is combined with Levocabastine.Approved
LevocetirizineThe risk or severity of adverse effects can be increased when Levetiracetam is combined with Levocetirizine.Approved
LevodopaThe risk or severity of adverse effects can be increased when Levetiracetam is combined with Levodopa.Approved
LevofloxacinThe serum concentration of Levetiracetam can be increased when it is combined with Levofloxacin.Approved, Investigational
Levomethadyl AcetateThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Levetiracetam.Approved
LevomilnacipranThe risk or severity of adverse effects can be increased when Levetiracetam is combined with Levomilnacipran.Approved
LevorphanolThe risk or severity of adverse effects can be increased when Levorphanol is combined with Levetiracetam.Approved
LevothyroxineThe serum concentration of Levetiracetam can be decreased when it is combined with Levothyroxine.Approved
LidocaineThe serum concentration of Levetiracetam can be increased when it is combined with Lidocaine.Approved, Vet Approved
LiothyronineThe serum concentration of Levetiracetam can be decreased when it is combined with Liothyronine.Approved, Vet Approved
LiotrixThe serum concentration of Levetiracetam can be decreased when it is combined with Liotrix.Approved
LisinoprilThe serum concentration of Levetiracetam can be increased when it is combined with Lisinopril.Approved, Investigational
LithiumThe risk or severity of adverse effects can be increased when Lithium is combined with Levetiracetam.Approved
LofentanilThe risk or severity of adverse effects can be increased when Lofentanil is combined with Levetiracetam.Illicit
LomitapideThe serum concentration of Levetiracetam can be increased when it is combined with Lomitapide.Approved
LoperamideThe serum concentration of Levetiracetam can be increased when it is combined with Loperamide.Approved
LopinavirThe serum concentration of Levetiracetam can be increased when it is combined with Lopinavir.Approved
LoratadineThe serum concentration of Levetiracetam can be increased when it is combined with Loratadine.Approved
LorazepamThe risk or severity of adverse effects can be increased when Lorazepam is combined with Levetiracetam.Approved
LosartanThe serum concentration of Levetiracetam can be increased when it is combined with Losartan.Approved
LovastatinThe serum concentration of Levetiracetam can be increased when it is combined with Lovastatin.Approved, Investigational
LoxapineThe risk or severity of adverse effects can be increased when Loxapine is combined with Levetiracetam.Approved
Lu AA21004The risk or severity of adverse effects can be increased when Lu AA21004 is combined with Levetiracetam.Investigational
LumacaftorThe serum concentration of Levetiracetam can be decreased when it is combined with Lumacaftor.Approved
LurasidoneThe risk or severity of adverse effects can be increased when Lurasidone is combined with Levetiracetam.Approved
Magnesium SulfateMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Levetiracetam.Approved, Vet Approved
MaprotilineThe serum concentration of Levetiracetam can be increased when it is combined with Maprotiline.Approved
MebendazoleThe serum concentration of Levetiracetam can be increased when it is combined with Mebendazole.Approved, Vet Approved
MeclizineThe risk or severity of adverse effects can be increased when Meclizine is combined with Levetiracetam.Approved
MedetomidineThe risk or severity of adverse effects can be increased when Medetomidine is combined with Levetiracetam.Vet Approved
MefloquineThe therapeutic efficacy of Levetiracetam can be decreased when used in combination with Mefloquine.Approved
Megestrol acetateThe serum concentration of Levetiracetam can be increased when it is combined with Megestrol acetate.Approved, Vet Approved
MelatoninThe risk or severity of adverse effects can be increased when Melatonin is combined with Levetiracetam.Approved, Nutraceutical, Vet Approved
MelperoneThe risk or severity of adverse effects can be increased when Melperone is combined with Levetiracetam.Approved
MepivacaineThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Levetiracetam.Approved, Vet Approved
MeprobamateThe serum concentration of Levetiracetam can be increased when it is combined with Meprobamate.Approved, Illicit
MesoridazineThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Levetiracetam.Approved
MetaxaloneThe risk or severity of adverse effects can be increased when Metaxalone is combined with Levetiracetam.Approved
MethadoneThe serum concentration of Levetiracetam can be increased when it is combined with Methadone.Approved
Methadyl AcetateThe risk or severity of adverse effects can be increased when Methadyl Acetate is combined with Levetiracetam.Approved, Illicit
MethapyrileneThe risk or severity of adverse effects can be increased when Methapyrilene is combined with Levetiracetam.Withdrawn
MethaqualoneThe risk or severity of adverse effects can be increased when Methaqualone is combined with Levetiracetam.Illicit, Withdrawn
MethocarbamolThe risk or severity of adverse effects can be increased when Methocarbamol is combined with Levetiracetam.Approved, Vet Approved
MethohexitalThe risk or severity of adverse effects can be increased when Methohexital is combined with Levetiracetam.Approved
MethotrimeprazineLevetiracetam may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved
MethoxyfluraneThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with Levetiracetam.Approved, Vet Approved
MethsuximideThe risk or severity of adverse effects can be increased when Levetiracetam is combined with Methsuximide.Approved
MethylphenobarbitalThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Levetiracetam.Approved
MetoprololThe serum concentration of Levetiracetam can be increased when it is combined with Metoprolol.Approved, Investigational
MetyrosineLevetiracetam may increase the sedative activities of Metyrosine.Approved
MianserinThe therapeutic efficacy of Levetiracetam can be decreased when used in combination with Mianserin.Approved
MibefradilThe serum concentration of Levetiracetam can be increased when it is combined with Mibefradil.Withdrawn
MiconazoleThe serum concentration of Levetiracetam can be increased when it is combined with Miconazole.Approved, Investigational, Vet Approved
MidazolamThe serum concentration of Levetiracetam can be decreased when it is combined with Midazolam.Approved, Illicit
MifepristoneThe serum concentration of Levetiracetam can be decreased when it is combined with Mifepristone.Approved, Investigational
MilnacipranThe risk or severity of adverse effects can be increased when Levetiracetam is combined with Milnacipran.Approved
MinocyclineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Levetiracetam.Approved, Investigational
MirtazapineLevetiracetam may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.Approved
MitomycinThe serum concentration of Levetiracetam can be increased when it is combined with Mitomycin.Approved
MitoxantroneThe serum concentration of Levetiracetam can be decreased when it is combined with Mitoxantrone.Approved, Investigational
MolindoneThe risk or severity of adverse effects can be increased when Molindone is combined with Levetiracetam.Approved
MorphineThe serum concentration of Levetiracetam can be increased when it is combined with Morphine.Approved, Investigational
NabiloneNabilone may increase the central nervous system depressant (CNS depressant) activities of Levetiracetam.Approved, Investigational
NalbuphineThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Levetiracetam.Approved
NaltrexoneThe serum concentration of Levetiracetam can be increased when it is combined with Naltrexone.Approved, Investigational, Vet Approved
NaringeninThe serum concentration of Levetiracetam can be increased when it is combined with Naringenin.Experimental
NefazodoneThe serum concentration of Levetiracetam can be decreased when it is combined with Nefazodone.Approved, Withdrawn
NelfinavirThe serum concentration of Levetiracetam can be decreased when it is combined with Nelfinavir.Approved
NeostigmineThe serum concentration of Levetiracetam can be increased when it is combined with Neostigmine.Approved, Vet Approved
NicardipineThe serum concentration of Levetiracetam can be increased when it is combined with Nicardipine.Approved
NifedipineThe serum concentration of Levetiracetam can be decreased when it is combined with Nifedipine.Approved
NilotinibThe serum concentration of Levetiracetam can be increased when it is combined with Nilotinib.Approved, Investigational
NisoldipineThe serum concentration of Levetiracetam can be increased when it is combined with Nisoldipine.Approved
NitrazepamThe serum concentration of Levetiracetam can be increased when it is combined with Nitrazepam.Approved
NitrendipineThe serum concentration of Levetiracetam can be increased when it is combined with Nitrendipine.Approved
Nitrous oxideThe risk or severity of adverse effects can be increased when Nitrous oxide is combined with Levetiracetam.Approved, Vet Approved
NorethisteroneThe serum concentration of Levetiracetam can be decreased when it is combined with Norethisterone.Approved
NormethadoneThe risk or severity of adverse effects can be increased when Normethadone is combined with Levetiracetam.Approved, Illicit
NortriptylineThe risk or severity of adverse effects can be increased when Nortriptyline is combined with Levetiracetam.Approved
OlanzapineThe risk or severity of adverse effects can be increased when Olanzapine is combined with Levetiracetam.Approved, Investigational
OlopatadineThe risk or severity of adverse effects can be increased when Olopatadine is combined with Levetiracetam.Approved
OmeprazoleThe serum concentration of Levetiracetam can be increased when it is combined with Omeprazole.Approved, Investigational, Vet Approved
OndansetronThe risk or severity of adverse effects can be increased when Ondansetron is combined with Levetiracetam.Approved
OpiumThe risk or severity of adverse effects can be increased when Opium is combined with Levetiracetam.Approved, Illicit
OrlistatThe serum concentration of Levetiracetam can be decreased when it is combined with Orlistat.Approved, Investigational
OrphenadrineLevetiracetam may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.Approved
OsanetantThe risk or severity of adverse effects can be increased when Osanetant is combined with Levetiracetam.Investigational
OxazepamThe risk or severity of adverse effects can be increased when Oxazepam is combined with Levetiracetam.Approved
OxetacaineThe risk or severity of adverse effects can be increased when Levetiracetam is combined with Oxetacaine.Investigational
OxprenololThe risk or severity of adverse effects can be increased when Oxprenolol is combined with Levetiracetam.Approved
OxybuprocaineThe risk or severity of adverse effects can be increased when Oxybuprocaine is combined with Levetiracetam.Approved
OxycodoneThe risk or severity of adverse effects can be increased when Oxycodone is combined with Levetiracetam.Approved, Illicit, Investigational
OxymorphoneThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Levetiracetam.Approved, Investigational, Vet Approved
P-NitrophenolThe serum concentration of Levetiracetam can be increased when it is combined with P-Nitrophenol.Experimental
PaclitaxelThe serum concentration of Levetiracetam can be increased when it is combined with Paclitaxel.Approved, Vet Approved
PaliperidoneThe risk or severity of adverse effects can be increased when Paliperidone is combined with Levetiracetam.Approved
Palmitic AcidThe serum concentration of Levetiracetam can be increased when it is combined with Palmitic Acid.Experimental
PantoprazoleThe serum concentration of Levetiracetam can be increased when it is combined with Pantoprazole.Approved
ParaldehydeLevetiracetam may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.Approved
ParoxetineThe serum concentration of Levetiracetam can be increased when it is combined with Paroxetine.Approved, Investigational
PentazocineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Levetiracetam.Approved, Vet Approved
PentobarbitalThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Levetiracetam.Approved, Vet Approved
PerampanelPerampanel may increase the central nervous system depressant (CNS depressant) activities of Levetiracetam.Approved
PerazineThe risk or severity of adverse effects can be increased when Levetiracetam is combined with Perazine.Investigational
PerindoprilThe serum concentration of Levetiracetam can be increased when it is combined with Perindopril.Approved
PerospironeThe risk or severity of adverse effects can be increased when Perospirone is combined with Levetiracetam.Approved
PerphenazineThe risk or severity of adverse effects can be increased when Perphenazine is combined with Levetiracetam.Approved
PethidineThe risk or severity of adverse effects can be increased when Pethidine is combined with Levetiracetam.Approved
PhenobarbitalThe serum concentration of Levetiracetam can be decreased when it is combined with Phenobarbital.Approved
PhenoxyethanolThe risk or severity of adverse effects can be increased when Phenoxyethanol is combined with Levetiracetam.Approved
PhenytoinThe risk or severity of adverse effects can be increased when Phenytoin is combined with Levetiracetam.Approved, Vet Approved
PimozideThe serum concentration of Levetiracetam can be increased when it is combined with Pimozide.Approved
PipamperoneThe risk or severity of adverse effects can be increased when Pipamperone is combined with Levetiracetam.Approved
PipotiazineThe risk or severity of adverse effects can be increased when Levetiracetam is combined with Pipotiazine.Approved
PiritramideThe risk or severity of adverse effects can be increased when Levetiracetam is combined with Piritramide.Investigational
PizotifenThe risk or severity of adverse effects can be increased when Levetiracetam is combined with Pizotifen.Approved
Platelet Activating FactorThe serum concentration of Levetiracetam can be decreased when it is combined with Platelet Activating Factor.Experimental
PomalidomideThe risk or severity of adverse effects can be increased when Levetiracetam is combined with Pomalidomide.Approved
PonatinibThe serum concentration of Levetiracetam can be increased when it is combined with Ponatinib.Approved
PosaconazoleThe serum concentration of Levetiracetam can be increased when it is combined with Posaconazole.Approved, Investigational, Vet Approved
PramipexoleLevetiracetam may increase the sedative activities of Pramipexole.Approved, Investigational
PramocaineThe risk or severity of adverse effects can be increased when Pramocaine is combined with Levetiracetam.Approved
PravastatinThe serum concentration of Levetiracetam can be increased when it is combined with Pravastatin.Approved
PrazepamThe risk or severity of adverse effects can be increased when Prazepam is combined with Levetiracetam.Approved, Illicit
PrazosinThe serum concentration of Levetiracetam can be increased when it is combined with Prazosin.Approved
PrednisoneThe serum concentration of Levetiracetam can be increased when it is combined with Prednisone.Approved, Vet Approved
PregabalinThe risk or severity of adverse effects can be increased when Pregabalin is combined with Levetiracetam.Approved, Illicit, Investigational
PregnanoloneThe risk or severity of adverse effects can be increased when Levetiracetam is combined with Pregnanolone.Investigational
PrilocaineThe risk or severity of adverse effects can be increased when Prilocaine is combined with Levetiracetam.Approved
PrimidoneThe risk or severity of adverse effects can be increased when Primidone is combined with Levetiracetam.Approved, Vet Approved
ProbenecidThe serum concentration of Levetiracetam can be increased when it is combined with Probenecid.Approved
ProcaineThe risk or severity of adverse effects can be increased when Procaine is combined with Levetiracetam.Approved, Investigational, Vet Approved
ProchlorperazineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Levetiracetam.Approved, Vet Approved
ProgesteroneThe serum concentration of Levetiracetam can be decreased when it is combined with Progesterone.Approved, Vet Approved
PromazineThe risk or severity of adverse effects can be increased when Promazine is combined with Levetiracetam.Approved, Vet Approved
PromethazineThe serum concentration of Levetiracetam can be increased when it is combined with Promethazine.Approved
PropafenoneThe serum concentration of Levetiracetam can be increased when it is combined with Propafenone.Approved
ProparacaineThe risk or severity of adverse effects can be increased when Proparacaine is combined with Levetiracetam.Approved, Vet Approved
PropofolThe risk or severity of adverse effects can be increased when Propofol is combined with Levetiracetam.Approved, Investigational, Vet Approved
PropoxycaineThe risk or severity of adverse effects can be increased when Propoxycaine is combined with Levetiracetam.Approved
PropranololThe serum concentration of Levetiracetam can be increased when it is combined with Propranolol.Approved, Investigational
ProtriptylineThe serum concentration of Levetiracetam can be increased when it is combined with Protriptyline.Approved
PSD502The risk or severity of adverse effects can be increased when PSD502 is combined with Levetiracetam.Investigational
QuazepamThe risk or severity of adverse effects can be increased when Quazepam is combined with Levetiracetam.Approved, Illicit
QuercetinThe serum concentration of Levetiracetam can be increased when it is combined with Quercetin.Experimental
QuetiapineThe risk or severity of adverse effects can be increased when Quetiapine is combined with Levetiracetam.Approved
QuinacrineThe serum concentration of Levetiracetam can be increased when it is combined with Quinacrine.Approved
QuinidineThe serum concentration of Levetiracetam can be increased when it is combined with Quinidine.Approved
QuinineThe serum concentration of Levetiracetam can be increased when it is combined with Quinine.Approved
RacloprideThe risk or severity of adverse effects can be increased when Levetiracetam is combined with Raclopride.Investigational
RamelteonThe risk or severity of adverse effects can be increased when Ramelteon is combined with Levetiracetam.Approved, Investigational
RanitidineThe serum concentration of Levetiracetam can be increased when it is combined with Ranitidine.Approved
RanolazineThe serum concentration of Levetiracetam can be increased when it is combined with Ranolazine.Approved, Investigational
ReboxetineThe serum concentration of Levetiracetam can be increased when it is combined with Reboxetine.Approved, Investigational
RegorafenibThe serum concentration of Levetiracetam can be increased when it is combined with Regorafenib.Approved
RemifentanilThe risk or severity of adverse effects can be increased when Remifentanil is combined with Levetiracetam.Approved
RemoxiprideThe risk or severity of adverse effects can be increased when Remoxipride is combined with Levetiracetam.Approved, Withdrawn
ReserpineThe serum concentration of Levetiracetam can be decreased when it is combined with Reserpine.Approved
RifampicinThe serum concentration of Levetiracetam can be decreased when it is combined with Rifampicin.Approved
RilpivirineThe serum concentration of Levetiracetam can be increased when it is combined with Rilpivirine.Approved
RisperidoneThe risk or severity of adverse effects can be increased when Risperidone is combined with Levetiracetam.Approved, Investigational
RitanserinThe risk or severity of adverse effects can be increased when Levetiracetam is combined with Ritanserin.Investigational
RitonavirThe serum concentration of Levetiracetam can be decreased when it is combined with Ritonavir.Approved, Investigational
RolapitantThe serum concentration of Levetiracetam can be increased when it is combined with Rolapitant.Approved
RomifidineThe risk or severity of adverse effects can be increased when Romifidine is combined with Levetiracetam.Vet Approved
RopiniroleLevetiracetam may increase the sedative activities of Ropinirole.Approved, Investigational
RopivacaineThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Levetiracetam.Approved
RotigotineLevetiracetam may increase the sedative activities of Rotigotine.Approved
RufinamideThe risk or severity of adverse effects can be increased when Rufinamide is combined with Levetiracetam.Approved
S-EthylisothioureaThe risk or severity of adverse effects can be increased when S-Ethylisothiourea is combined with Levetiracetam.Experimental
Sage 547The risk or severity of adverse effects can be increased when Levetiracetam is combined with Sage 547.Investigational
SaquinavirThe serum concentration of Levetiracetam can be decreased when it is combined with Saquinavir.Approved, Investigational
ScopolamineThe serum concentration of Levetiracetam can be increased when it is combined with Scopolamine.Approved
SecobarbitalThe risk or severity of adverse effects can be increased when Secobarbital is combined with Levetiracetam.Approved, Vet Approved
SelegilineThe serum concentration of Levetiracetam can be increased when it is combined with Selegiline.Approved, Investigational, Vet Approved
SertindoleThe risk or severity of adverse effects can be increased when Sertindole is combined with Levetiracetam.Approved, Withdrawn
SertralineThe serum concentration of Levetiracetam can be increased when it is combined with Sertraline.Approved
SevofluraneThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Levetiracetam.Approved, Vet Approved
SimeprevirThe serum concentration of Levetiracetam can be increased when it is combined with Simeprevir.Approved
SimvastatinThe serum concentration of Levetiracetam can be increased when it is combined with Simvastatin.Approved
SirolimusThe serum concentration of Levetiracetam can be decreased when it is combined with Sirolimus.Approved, Investigational
Sodium oxybateSodium oxybate may increase the central nervous system depressant (CNS depressant) activities of Levetiracetam.Approved
SorafenibThe serum concentration of Levetiracetam can be increased when it is combined with Sorafenib.Approved, Investigational
SpironolactoneThe serum concentration of Levetiracetam can be increased when it is combined with Spironolactone.Approved
St. John's WortThe serum concentration of Levetiracetam can be decreased when it is combined with St. John&#39;s Wort.Nutraceutical
StaurosporineThe serum concentration of Levetiracetam can be increased when it is combined with Staurosporine.Experimental
StiripentolThe risk or severity of adverse effects can be increased when Levetiracetam is combined with Stiripentol.Approved
StreptozocinThe serum concentration of Levetiracetam can be decreased when it is combined with Streptozocin.Approved
SufentanilThe risk or severity of adverse effects can be increased when Sufentanil is combined with Levetiracetam.Approved, Investigational
SulfinpyrazoneThe serum concentration of Levetiracetam can be increased when it is combined with Sulfinpyrazone.Approved
SulpirideThe risk or severity of adverse effects can be increased when Sulpiride is combined with Levetiracetam.Approved
SumatriptanThe serum concentration of Levetiracetam can be increased when it is combined with Sumatriptan.Approved, Investigational
SunitinibThe serum concentration of Levetiracetam can be increased when it is combined with Sunitinib.Approved, Investigational
SuvorexantLevetiracetam may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.Approved
TacrineThe serum concentration of Levetiracetam can be increased when it is combined with Tacrine.Withdrawn
TacrolimusThe serum concentration of Levetiracetam can be decreased when it is combined with Tacrolimus.Approved, Investigational
TamoxifenThe serum concentration of Levetiracetam can be decreased when it is combined with Tamoxifen.Approved
TandospironeThe risk or severity of adverse effects can be increased when Levetiracetam is combined with Tandospirone.Investigational
TapentadolTapentadol may increase the central nervous system depressant (CNS depressant) activities of Levetiracetam.Approved
TasimelteonThe risk or severity of adverse effects can be increased when Levetiracetam is combined with Tasimelteon.Approved
Taurocholic AcidThe serum concentration of Levetiracetam can be increased when it is combined with Taurocholic Acid.Experimental
TelmisartanThe serum concentration of Levetiracetam can be increased when it is combined with Telmisartan.Approved, Investigational
TemazepamThe risk or severity of adverse effects can be increased when Temazepam is combined with Levetiracetam.Approved
TemsirolimusThe serum concentration of Levetiracetam can be increased when it is combined with Temsirolimus.Approved
TerazosinThe serum concentration of Levetiracetam can be increased when it is combined with Terazosin.Approved
TerfenadineThe serum concentration of Levetiracetam can be increased when it is combined with Terfenadine.Withdrawn
TesmilifeneThe serum concentration of Levetiracetam can be decreased when it is combined with Tesmilifene.Investigational
TestosteroneThe serum concentration of Levetiracetam can be increased when it is combined with Testosterone.Approved, Investigational
TetrabenazineThe risk or severity of adverse effects can be increased when Levetiracetam is combined with Tetrabenazine.Approved
TetracaineThe risk or severity of adverse effects can be increased when Tetracaine is combined with Levetiracetam.Approved, Vet Approved
TetrodotoxinThe risk or severity of adverse effects can be increased when Tetrodotoxin is combined with Levetiracetam.Investigational
ThalidomideLevetiracetam may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.Approved, Investigational, Withdrawn
ThiamylalThe risk or severity of adverse effects can be increased when Thiamylal is combined with Levetiracetam.Approved, Vet Approved
ThiopentalThe risk or severity of adverse effects can be increased when Thiopental is combined with Levetiracetam.Approved, Vet Approved
ThioridazineThe risk or severity of adverse effects can be increased when Thioridazine is combined with Levetiracetam.Approved
ThiothixeneThe risk or severity of adverse effects can be increased when Thiothixene is combined with Levetiracetam.Approved
TiagabineThe risk or severity of adverse effects can be increased when Tiagabine is combined with Levetiracetam.Approved
TiaprideThe risk or severity of adverse effects can be increased when Levetiracetam is combined with Tiapride.Investigational
TicagrelorThe serum concentration of Levetiracetam can be increased when it is combined with Ticagrelor.Approved
TiletamineThe risk or severity of adverse effects can be increased when Tiletamine is combined with Levetiracetam.Vet Approved
TizanidineThe risk or severity of adverse effects can be increased when Tizanidine is combined with Levetiracetam.Approved
TolcaponeThe risk or severity of adverse effects can be increased when Tolcapone is combined with Levetiracetam.Approved, Withdrawn
TolvaptanThe serum concentration of Levetiracetam can be increased when it is combined with Tolvaptan.Approved
TopiramateThe risk or severity of adverse effects can be increased when Topiramate is combined with Levetiracetam.Approved
TramadolThe risk or severity of adverse effects can be increased when Tramadol is combined with Levetiracetam.Approved, Investigational
Trans-2-PhenylcyclopropylamineThe risk or severity of adverse effects can be increased when Trans-2-Phenylcyclopropylamine is combined with Levetiracetam.Experimental
TranylcypromineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Levetiracetam.Approved
TrazodoneThe serum concentration of Levetiracetam can be decreased when it is combined with Trazodone.Approved, Investigational
TriazolamThe risk or severity of adverse effects can be increased when Triazolam is combined with Levetiracetam.Approved
TrifluoperazineThe serum concentration of Levetiracetam can be increased when it is combined with Trifluoperazine.Approved
TriflupromazineThe serum concentration of Levetiracetam can be increased when it is combined with Triflupromazine.Approved, Vet Approved
TrimethoprimThe serum concentration of Levetiracetam can be decreased when it is combined with Trimethoprim.Approved, Vet Approved
TrimipramineThe serum concentration of Levetiracetam can be increased when it is combined with Trimipramine.Approved
TriprolidineThe risk or severity of adverse effects can be increased when Triprolidine is combined with Levetiracetam.Approved
TroleandomycinThe serum concentration of Levetiracetam can be increased when it is combined with Troleandomycin.Approved
Uc1010The risk or severity of adverse effects can be increased when Levetiracetam is combined with Uc1010.Investigational
Valproic AcidThe risk or severity of adverse effects can be increased when Valproic Acid is combined with Levetiracetam.Approved, Investigational
VenlafaxineThe serum concentration of Levetiracetam can be increased when it is combined with Venlafaxine.Approved
VerapamilThe serum concentration of Levetiracetam can be decreased when it is combined with Verapamil.Approved
VigabatrinThe risk or severity of adverse effects can be increased when Vigabatrin is combined with Levetiracetam.Approved
VinblastineThe serum concentration of Levetiracetam can be decreased when it is combined with Vinblastine.Approved
VincristineThe serum concentration of Levetiracetam can be decreased when it is combined with Vincristine.Approved, Investigational
VinorelbineThe serum concentration of Levetiracetam can be increased when it is combined with Vinorelbine.Approved, Investigational
VortioxetineThe risk or severity of adverse effects can be increased when Vortioxetine is combined with Levetiracetam.Approved
XylazineThe risk or severity of adverse effects can be increased when Xylazine is combined with Levetiracetam.Vet Approved
ZaleplonThe risk or severity of adverse effects can be increased when Zaleplon is combined with Levetiracetam.Approved, Illicit, Investigational
ZiconotideThe risk or severity of adverse effects can be increased when Levetiracetam is combined with Ziconotide.Approved
ZimelidineThe serum concentration of Levetiracetam can be increased when it is combined with Zimelidine.Withdrawn
ZiprasidoneThe risk or severity of adverse effects can be increased when Ziprasidone is combined with Levetiracetam.Approved
ZolazepamThe risk or severity of adverse effects can be increased when Zolazepam is combined with Levetiracetam.Vet Approved
ZolpidemLevetiracetam may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.Approved
ZonisamideThe risk or severity of adverse effects can be increased when Zonisamide is combined with Levetiracetam.Approved, Investigational
ZopicloneThe risk or severity of adverse effects can be increased when Zopiclone is combined with Levetiracetam.Approved
ZotepineThe risk or severity of adverse effects can be increased when Zotepine is combined with Levetiracetam.Approved
ZuclopenthixolThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Levetiracetam.Approved, Investigational
Food Interactions
  • Take without regard to meals. Food does not affect bioavailabilty.
References
Synthesis Reference

Tooru Futagawa, Jean-Pierre Canvat, Emile Cavoy, Michel Deleers, Michel Hamende, Vincent Zimmermann, “Process for the preparation of levetiracetam.” U.S. Patent US6107492, issued September, 1996.

US6107492
General ReferencesNot Available
External Links
ATC CodesN03AX14
AHFS Codes
  • 28:12.92
PDB EntriesNot Available
FDA labelDownload (52.5 KB)
MSDSNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.988
Blood Brain Barrier+0.9821
Caco-2 permeable-0.6114
P-glycoprotein substrateSubstrate0.5137
P-glycoprotein inhibitor INon-inhibitor0.5612
P-glycoprotein inhibitor IINon-inhibitor0.8786
Renal organic cation transporterNon-inhibitor0.7024
CYP450 2C9 substrateNon-substrate0.8801
CYP450 2D6 substrateNon-substrate0.8184
CYP450 3A4 substrateNon-substrate0.5191
CYP450 1A2 substrateNon-inhibitor0.9394
CYP450 2C9 inhibitorNon-inhibitor0.7603
CYP450 2D6 inhibitorNon-inhibitor0.9471
CYP450 2C19 inhibitorNon-inhibitor0.8459
CYP450 3A4 inhibitorNon-inhibitor0.9669
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.9502
Ames testNon AMES toxic0.8783
CarcinogenicityNon-carcinogens0.9094
BiodegradationNot ready biodegradable0.9305
Rat acute toxicity2.1707 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9206
hERG inhibition (predictor II)Non-inhibitor0.8735
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
ManufacturersNot Available
Packagers
Dosage forms
FormRouteStrength
Tablet, extended releaseOral1000 mg/1
Tablet, extended releaseOral1500 mg/1
TabletOral250 mg
TabletOral500 mg
TabletOral750 mg
InjectionIntravenous10 mg/mL
InjectionIntravenous100 mg/mL
InjectionIntravenous15 mg/mL
InjectionIntravenous5 mg/mL
Injection, solutionIntravenous100 mg/mL
Injection, solutionIntravenous500 mg/5mL
Injection, solution, concentrateIntravenous100 mg/mL
Injection, solution, concentrateIntravenous500 mg/5mL
SolutionOral100 mg/mL
SolutionOral100 mg/5mL
TabletOral1000 mg/1
TabletOral250 mg/1
TabletOral500 mg/1
TabletOral750 mg/1
Tablet, extended releaseOral500 mg/1
Tablet, extended releaseOral750 mg/1
Tablet, film coatedOral1000 mg/1
Tablet, film coatedOral250 mg/1
Tablet, film coatedOral500 mg/1
Tablet, film coatedOral750 mg/1
Tablet, film coated, extended releaseOral1000 mg/1
Tablet, film coated, extended releaseOral500 mg/1
Tablet, film coated, extended releaseOral750 mg/1
Tablet, film coatedOral1000 mg
Tablet, film coatedOral250 mg
Tablet, film coatedOral500 mg
Tablet, film coatedOral750 mg
Solution, concentrateIntravenous100 mg/ml
Tablet, for suspensionOral1000 mg/1
Tablet, for suspensionOral250 mg/1
Tablet, for suspensionOral500 mg/1
Tablet, for suspensionOral750 mg/1
Prices
Unit descriptionCostUnit
Keppra 500 mg/5 ml vial9.28USD ml
Keppra 1000 mg tablet9.01USD tablet
Levetiracetam 1000 mg tablet7.18USD tablet
Keppra xr 750 mg tablet6.46USD tablet
Keppra xr 500 mg tablet6.43USD tablet
Keppra 500 mg tablet5.09USD tablet
Levetiracetam 750 mg tablet4.86USD tablet
Keppra 750 mg tablet4.74USD tablet
Keppra XR 500 mg 24 Hour tablet4.47USD tablet
Keppra 250 mg tablet3.62USD tablet
Levetiracetam 500 mg tablet3.59USD tablet
Levetiracetam 250 mg tablet2.93USD tablet
Apo-Levetiracetam 750 mg Tablet1.7USD tablet
Co Levetiracetam 750 mg Tablet1.7USD tablet
Pms-Levetiracetam 750 mg Tablet1.7USD tablet
Apo-Levetiracetam 500 mg Tablet1.23USD tablet
Co Levetiracetam 500 mg Tablet1.23USD tablet
Pms-Levetiracetam 500 mg Tablet1.23USD tablet
Apo-Levetiracetam 250 mg Tablet1.01USD tablet
Co Levetiracetam 250 mg Tablet1.01USD tablet
Pms-Levetiracetam 250 mg Tablet1.01USD tablet
Keppra 100 mg/ml Solution0.95USD ml
Levetiracetam 100 mg/ml Solution0.68USD ml
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
US6471992 No1998-02-202018-02-20Us
US7858122 No2008-09-172028-09-17Us
US8802142 Yes2011-12-072031-12-07Us
Properties
StateSolid
Experimental Properties
PropertyValueSource
logP-0.6Not Available
Predicted Properties
PropertyValueSource
Water Solubility298.0 mg/mLALOGPS
logP-0.64ALOGPS
logP-0.59ChemAxon
logS0.24ALOGPS
pKa (Strongest Acidic)16.09ChemAxon
pKa (Strongest Basic)-1.6ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count2ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area63.4 Å2ChemAxon
Rotatable Bond Count3ChemAxon
Refractivity44.08 m3·mol-1ChemAxon
Polarizability17.79 Å3ChemAxon
Number of Rings1ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
SpectraNot Available
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as alpha amino acids and derivatives. These are amino acids in which the amino group is attached to the carbon atom immediately adjacent to the carboxylate group (alpha carbon), or a derivative thereof.
KingdomOrganic compounds
Super ClassOrganic acids and derivatives
ClassCarboxylic acids and derivatives
Sub ClassAmino acids, peptides, and analogues
Direct ParentAlpha amino acids and derivatives
Alternative Parents
Substituents
  • Alpha-amino acid or derivatives
  • Fatty amide
  • Pyrrolidone
  • 2-pyrrolidone
  • N-alkylpyrrolidine
  • Fatty acyl
  • Tertiary carboxylic acid amide
  • Pyrrolidine
  • Carboxamide group
  • Primary carboxylic acid amide
  • Lactam
  • Organoheterocyclic compound
  • Azacycle
  • Carbonyl group
  • Organic nitrogen compound
  • Organooxygen compound
  • Organonitrogen compound
  • Hydrocarbon derivative
  • Organic oxide
  • Organic oxygen compound
  • Aliphatic heteromonocyclic compound
Molecular FrameworkAliphatic heteromonocyclic compounds
External Descriptors

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
agonist
General Function:
Transmembrane transporter activity
Specific Function:
Plays a role in the control of regulated secretion in neural and endocrine cells, enhancing selectively low-frequency neurotransmission. Positively regulates vesicle fusion by maintaining the readily releasable pool of secretory vesicles (By similarity).
Gene Name:
SV2A
Uniprot ID:
Q7L0J3
Molecular Weight:
82694.665 Da
References
  1. Lynch BA, Lambeng N, Nocka K, Kensel-Hammes P, Bajjalieh SM, Matagne A, Fuks B: The synaptic vesicle protein SV2A is the binding site for the antiepileptic drug levetiracetam. Proc Natl Acad Sci U S A. 2004 Jun 29;101(26):9861-6. Epub 2004 Jun 21. [PubMed:15210974 ]
  2. Stahl SM: Psychopharmacology of anticonvulsants: levetiracetam as a synaptic vesicle protein modulator. J Clin Psychiatry. 2004 Sep;65(9):1162-3. [PubMed:15367040 ]
  3. Lambeng N, Grossmann M, Chatelain P, Fuks B: Solubilization and immunopurification of rat brain synaptic vesicle protein 2A with maintained binding properties. Neurosci Lett. 2006 May 1;398(1-2):107-12. Epub 2006 Jan 24. [PubMed:16434140 ]
  4. Gillard M, Chatelain P, Fuks B: Binding characteristics of levetiracetam to synaptic vesicle protein 2A (SV2A) in human brain and in CHO cells expressing the human recombinant protein. Eur J Pharmacol. 2006 Apr 24;536(1-2):102-8. Epub 2006 Mar 10. [PubMed:16556440 ]
  5. Newton HB, Dalton J, Goldlust S, Pearl D: Retrospective analysis of the efficacy and tolerability of levetiracetam in patients with metastatic brain tumors. J Neurooncol. 2007 Sep;84(3):293-6. Epub 2007 Apr 13. [PubMed:17431542 ]
  6. Johannessen Landmark C: Antiepileptic drugs in non-epilepsy disorders: relations between mechanisms of action and clinical efficacy. CNS Drugs. 2008;22(1):27-47. [PubMed:18072813 ]
  7. De Smedt T, Raedt R, Vonck K, Boon P: Levetiracetam: the profile of a novel anticonvulsant drug-part I: preclinical data. CNS Drug Rev. 2007 Spring;13(1):43-56. [PubMed:17461889 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Voltage-gated calcium channel activity
Specific Function:
Voltage-sensitive calcium channels (VSCC) mediate the entry of calcium ions into excitable cells and are also involved in a variety of calcium-dependent processes, including muscle contraction, hormone or neurotransmitter release, gene expression, cell motility, cell division and cell death. The isoform alpha-1B gives rise to N-type calcium currents. N-type calcium channels belong to the 'high-...
Gene Name:
CACNA1B
Uniprot ID:
Q00975
Molecular Weight:
262493.84 Da
References
  1. De Smedt T, Raedt R, Vonck K, Boon P: Levetiracetam: the profile of a novel anticonvulsant drug-part I: preclinical data. CNS Drug Rev. 2007 Spring;13(1):43-56. [PubMed:17461889 ]
  2. Lukyanetz EA, Shkryl VM, Kostyuk PG: Selective blockade of N-type calcium channels by levetiracetam. Epilepsia. 2002 Jan;43(1):9-18. [PubMed:11879381 ]

Transporters

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Xenobiotic-transporting atpase activity
Specific Function:
Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells.
Gene Name:
ABCB1
Uniprot ID:
P08183
Molecular Weight:
141477.255 Da
References
  1. Baltes S, Gastens AM, Fedrowitz M, Potschka H, Kaever V, Loscher W: Differences in the transport of the antiepileptic drugs phenytoin, levetiracetam and carbamazepine by human and mouse P-glycoprotein. Neuropharmacology. 2007 Feb;52(2):333-46. Epub 2006 Oct 10. [PubMed:17045309 ]
  2. Luna-Tortos C, Fedrowitz M, Loscher W: Several major antiepileptic drugs are substrates for human P-glycoprotein. Neuropharmacology. 2008 Dec;55(8):1364-75. doi: 10.1016/j.neuropharm.2008.08.032. Epub 2008 Sep 11. [PubMed:18824002 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Organic anion transmembrane transporter activity
Specific Function:
Mediates hepatobiliary excretion of numerous organic anions. May function as a cellular cisplatin transporter.
Gene Name:
ABCC2
Uniprot ID:
Q92887
Molecular Weight:
174205.64 Da
References
  1. Baltes S, Gastens AM, Fedrowitz M, Potschka H, Kaever V, Loscher W: Differences in the transport of the antiepileptic drugs phenytoin, levetiracetam and carbamazepine by human and mouse P-glycoprotein. Neuropharmacology. 2007 Feb;52(2):333-46. Epub 2006 Oct 10. [PubMed:17045309 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on December 09, 2016 03:54